

506, 994  
Recd PCT/PTO 04 SEP 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
WO 03/075840 A2

(51) International Patent Classification<sup>7</sup>:

A61K

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US03/06459

(22) International Filing Date: 4 March 2003 (04.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
60/361,783 4 March 2002 (04.03.2002) US

(71) Applicant (for all designated States except US): IM-  
CLONE SYSTEMS INCORPORATED [US/US]; 180  
Varick Street, New York, NY 10014 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHU, Zhenping  
[US/US]; 9 Boulder Run, Oakland, NJ 07436 (US).

(74) Agents: SOMERVILLE, Deborah, A. et al.; Kenyon &  
Kenyon, One Broadway, New York, NY 10004 (US).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

WO 03/075840

(54) Title: HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF

(57) Abstract: The invention provides an antibodies that bind to *KDR* with an affinity comparable to or higher than human VEGF, and that neutralizes activation of *KDR*. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of *KDR*, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.

**HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF****FIELD OF THE INVENTION**

[0001] The present invention is directed to human antibodies that bind to KDR, that block binding of KDR to vascular endothelial growth factor receptor (VEGFR), and that neutralize activation of KDR. The antibodies are used for treating neoplastic diseases and hyperproliferative disorders and can be used alone or in combination with other VEGFR antagonists and with epidermal growth factor receptor (EGFR) antagonists.

**BACKGROUND OF THE INVENTION**

[0002] Angiogenesis is a highly complex process of developing new blood vessels that involves the proliferation and migration of, and tissue infiltration by capillary endothelial cells from pre-existing blood vessels, cell assembly into tubular structures, joining of newly forming tubular assemblies to closed-circuit vascular systems, and maturation of newly formed capillary vessels.

[0003] Angiogenesis is important in normal physiological processes including embryonic development, follicular growth, and wound healing, as well as in pathological conditions such as tumor growth and in non-neoplastic diseases involving abnormal neovascularization, including neovascular glaucoma (Folkman, J. and Klagsbrun, M., *Science*, 235:442-7 (1987). Other disease states include but are not limited to, neoplastic diseases, including but not limited to solid tumors, atherosclerosis and other inflammatory diseases such as rheumatoid arthritis, and ophthalmological conditions such as diabetic retinopathy and age-related macular degeneration. Conditions or diseases to which persistent or uncontrolled angiogenesis contribute have been termed angiogenic dependent or angiogenic associated diseases.

[0004] One means for controlling such diseases and pathological conditions comprises restricting the blood supply to those cells involved in mediating or causing the disease or condition, for example, by occluding blood vessels supplying portions of organs in which tumors are present. Such approaches require the site of the tumor to be identified and are generally limited to treatment to a single site, or a small number of sites. An additional disadvantage of direct mechanical restriction of a blood supply is that collateral blood vessels develop, often quite rapidly, restoring the blood supply to the tumor.

[0005] Other approaches have focused on the modulation of factors that are involved in the regulation of angiogenesis. While usually quiescent, vascular endothelial proliferation is highly regulated, even during angiogenesis. VEGF is a factor that has been implicated as a regulator of angiogenesis *in vivo* (Klagsbrun, M. and D'Amore, P., *Annual Rev. Physiol.*, 53: 217-39 (1991)).

[0006] An endothelial-cell specific mitogen, VEGF, acts as an angiogenesis inducer by specifically promoting the proliferation of endothelial cells. It is a homodimeric glycoprotein consisting of two 23 kD subunits. Four different monomeric isoforms of VEGF resulting from alternative splicing of mRNA have been identified. These include two membrane bound forms (VEGF206 and VEGF189) and two soluble forms (VEGF165 and VEGF121). VEGF165 is the most abundant isoform in all human tissues except placenta.

[0007] VEGF is expressed in embryonic tissues (Breier et al., *Development*, 114:521-32 (1992)), macrophages, and proliferating epidermal keratinocytes during wound healing (Brown et al., *J. Exp. Med.*, 176:1375-9 (1992)), and may be responsible for tissue edema associated with inflammation (Ferrara et al., *Endocr. Rev.*, 13:18-32 (1992)). *In situ* hybridization studies have demonstrated high levels of VEGF expression in a number of human tumor lines including glioblastoma multiforme, hemangioblastoma, other central nervous system neoplasms and AIDS-associated Kaposi's sarcoma (Plate, K. et al., *Nature*, 359:845-8 (1992); Plate, K. et al., *Cancer Res.*, 53:5822-7 (1993); Berkman, R. et al., *J. Clin. Invest.*, 91:153-9 (1993); Nakamura, S. et al., AIDS Weekly, 13 (1) (1992)). High levels of VEGF expression has also been found in atherosclerotic lesions, plaques and in inflammatory cells.

[0008] VEGF mediates its biological effect through high affinity VEGF receptors which are selectively expressed on endothelial cells during, for example, embryogenesis (Millauer, B. et al. *Cell*, 72:835-46 (1993)) and tumor formation, and which have been implicated in modulating angiogenesis and tumor growth. These receptors comprise a tyrosine kinase cytosolic domain that initiates the signaling pathway involved in cell growth.

[0009] VEGF receptors typically are class III receptor-type tyrosine kinases characterized by having several, typically 5 or 7, immunoglobulin-like loops in their amino-terminal extracellular receptor ligand-binding domains (Kaipainen et al., *J. Exp. Med.*, 178:2077-88 (1993)). The other two regions include a transmembrane region and a carboxy-terminal intracellular catalytic domain interrupted by an insertion of hydrophilic interkinase

sequences of variable lengths, called the kinase insert domain (Terman et al., *Oncogene*, 6:1677-83 (1991)). VEGF receptors include fms-like tyrosine kinase receptor (flt-1), or VEGFR-1, sequenced by Shibuya et al., *Oncogene*, 5:519-24 (1990), kinase insert domain-containing receptor/fetal liver kinase (KDR/flk-1), or VEGFR-2, described in WO 92/14248, filed February 20, 1992, and Terman et al., *Oncogene*, 6:1677-83 (1991) and sequenced by Matthews et al., *Proc. Natl. Acad. Sci. USA*, 88:9026-30 (1991), although other receptors can also bind VEGF. Another tyrosine kinase receptor, VEGFR-3 (flt-4), binds the VEGF homologues VEGF-C and VEGF-D and is important in the development of lymphatic vessels.

[0010] Release of VEGF by a tumor mass stimulates angiogenesis in adjacent endothelial cells. When VEGF is expressed by the tumor mass, endothelial cells adjacent to the VEGF+ tumor cells will up-regulate expression of VEGF receptors, e.g., VEGFR-1 and VEGFR-2. It is generally believed that KDR/VEGFR-2 is the main VEGF signal transducer that results in endothelial cell proliferation, migration, differentiation, tube formation, increase of vascular permeability, and maintenance of vascular integrity. VEGFR-1 possesses a much weaker kinase activity, and is unable to generate a mitogenic response when stimulated by VEGF, although it binds to VEGF with an affinity that is approximately 10-fold higher than KDR. VEGFR-1 has also been implicated in VEGF and placenta growth factor (PIGF) induced migration of monocytes and macrophages and production of tissue factor.

[0011] High levels of VEGFR-2, for example, are expressed by endothelial cells that infiltrate gliomas (Plate, K. et al. (1992)), and are specifically upregulated by VEGF produced by human glioblastomas (Plate, K. et al. (1993)). The finding of high levels of VEGFR-2 expression in glioblastoma associated endothelial cells (GAEC) suggests that receptor activity is induced during tumor formation, since VEGFR-2 transcripts are barely detectable in normal brain endothelial cells, indicating generation of a paracrine VEGF/VEGFR loop. This upregulation is confined to the vascular endothelial cells in close proximity to the tumor. Blocking VEGF activity with neutralizing anti-VEGF monoclonal antibodies (mAbs) results in inhibition of the growth of human tumor xenografts in nude mice (Kim, K. et al. *Nature*, 362:841-4 (1993)), suggesting a direct role for VEGF in tumor-related angiogenesis.

[0012] Accordingly, VEGFR antagonists have been developed to treat vascularized tumors and other angiogenic diseases. These have included neutralizing antibodies that block

signaling by VEGF receptors expressed on vascular endothelial cells to reduce tumor growth by blocking angiogenesis through an endothelial-dependent paracrine loop. See, e.g., U.S. Patent No. 6,365,157 (Rockwell et al.), WO 00/44777 (Zhu et al.), WO 01/54723 (Kerbel); WO 01/74296 (Witte et al.), WO 01/90192 (Zhu), WO 03/002144 (Zhu), and WO 03/000183 (Carmeliet et al.).

[0013] VEGF receptors have also been found on some non-endothelial cells, such as tumor cells producing VEGF, wherein an endothelial-independent autocrine loop is generated to support tumor growth. For example, VEGF is almost invariably expressed by all established leukemic cell lines and freshly isolated human leukemias. Further, VEGFR-2 and VEGFR-1 are expressed by certain human leukemias. Fielder et al., *Blood* 89:1870-5 (1997); Bellamy et al., *Cancer Res.* 59:728-33 (1999). It has been demonstrated that a VEGF/human VEGFR-2 autocrine loop mediates leukemic cell survival and migration *in vivo*. Dias et al., *J. Clin. Invest.* 106:511-21 (2000); and WO 01/74296 (Witte et al.). Similarly, VEGF production and VEGFR expression also have been reported for some solid tumor cell lines *in vitro*. (See, Sato, K. et al., *Tohoku J. Exp. Med.*, 185: 173-84 (1998); Ishii, Y., *Nippon Sanka Fujinka Gakkai Zasshi*, 47: 133-40 (1995); and Ferrer, F.A. et al, *Urology*, 54:567-72 (1999)). It has further been demonstrated that VEGFR-1 Mabs inhibit an autocrine VEGFR/human VEGFR-1 loop in breast carcinoma cells. Wu, et al., "Monoclonal antibody against VEGFR1 inhibits flt1-positive DU4475 human breast tumor growth by a dual mechanism involving anti-angiogenic and tumor cell growth inhibitory activities," AACR NCI EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 29-Nov. 2, 2001, Abstract #7.

[0014] There remains a need for agents which inhibit VEGF receptor activity to treat or prevent VEGF-receptor dependent diseases or conditions, by inhibiting, for example, pathogenic angiogenesis or tumor growth through inhibition of the paracrine and/or autocrine VEGF/ VEGFR loop.

## SUMMARY OF THE INVENTION

[0015] The present invention provides human antibodies, and portions thereof that bind to KDR, block binding of vascular endothelial growth factor (VEGF) to KDR, and neutralize activation of KDR. The antibodies are used for treating neoplastic diseases, including, for example, solid and non-solid tumors. The antibodies can also be used for

treatment of hyperproliferative disorders. Accordingly, the invention provides methods of neutralizing the activation of KDR, methods of inhibiting tumor growth, including inhibition of tumor associated angiogenesis, and methods of treating other angiogenesis related disorders. The present invention provides kits having human antibodies or antibody fragments that bind to VEGR receptors.

[0016] The antibodies can be used alone or in combination with other VEGFR antagonists, and/or angiogenesis inhibitors such as, for example, epidermal growth factor receptor (EGFR) antagonists. The invention also provides nucleic acid molecules that encode the antibodies.

[0017] Abbreviations - VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; KDR, kinase insert domain-containing receptor (also known as VEGF receptor 2); *FLK-1*, fetal liver kinase 1; scFv, single chain Fv; HUVEC, human umbilical vein endothelial cells; PBS, 0.01M phosphate buffered saline (pH 7.2); PBST, PBS containing 0.1% Tween-20; AP, alkaline phosphatase; EGF, epidermal growth factor;  $V_H$  and  $V_L$ , variable domain of immunoglobulin heavy and light chain, respectively.

## DESCRIPTION OF THE FIGURES

[0018] Figure 1 shows the identification and expression of human anti-DKR Fab fragments. Fig. 1A: *Bst*N I digestion patterns of four neutralizing anti-KDR Fab. Fig. 1B: SDS-PAGE analysis of purified Fab fragments under nonreducing conditions. Lane 1, D1F7; Lane 2, D2C6; Lane 3, D1H4; Lane 4, D2H2.

[0019] Figure 2 depicts binding to KDR, blocking of KDR/VEGF interaction and blocking of Flk-1/VEGF interaction by human anti-KDR Fab fragments.

Fig. 2A: Dose-dependent binding of human anti-KDR Fab to immobilized KDR. Fig. 2B: Inhibition of KDR binding to immobilized VEGF by anti-KDR Fab. Fig. 2C: Inhibition of Flk-1 binding to immobilized VEGF by anti-KDR Fab. Various amounts of Fab proteins were incubated with a fixed amount of KDR-AP (2B) or Flk-1-AP (2C) in solution at RT for 1 h.

[0020] Figure 3 depicts epitope mapping for the anti-KDR Fab fragments. KDR-AP, its domain deletion-AP variants, and Flk-1-AP were captured on a 96-well plate and incubated with human anti-KDR Fab fragments. Data are presented relative to binding of the Fab fragments to full-length KDR.

[0021] Figure 4 depicts inhibition of VEGF-induced HUVEC mitogenesis by human anti-KDR Fab fragments. Various amounts of anti-KDR Fab fragments were added to duplicate wells and incubated at 37°C for 1 h, after which VEGF was added to the wells to a final concentration of 16 ng/ml. Cells were harvested and DNA incorporated radioactivity was determined.

[0022] Figure 5 depicts inhibition of VEGF-stimulated migration of human leukemia cells by the anti-KDR Fab fragments. Fig 5A: VEGF promotes migration of HL60 and HEL cells in a dose dependent manner. Fig. 5B: Inhibition of VEGF-stimulated migration of human leukemia cells by the anti-KDR Fab fragments. The amount of KDR-AP that bound to the immobilized VEGF was quantified by incubation of the plates with AP substrate and reading of A405nm.

[0023] Figure 6 depicts binding to KDR and blocking of KDR/VEGF interaction by human anti-KDR antibodies. Fig. 6A: Dose-dependent binding of anti-KDR to immobilized KDR. Various amounts of antibodies were incubated at RT for 1 h in 96-well plates coated with KDR. Fig. 6B: Inhibition of binding of KDR to immobilized VEGF by human anti-KDR antibodies. Various amounts of the antibodies were incubated with a fixed amount of KDR-AP in solution at RT for 1 hr.

[0024] Figure 7 depicts inhibition of VEGF binding and VEGF-induced mitogenesis of HUVEC. Fig. 7A: Inhibition of binding of radiolabeled VEGF to cell-surface KDR by human anti-KDR antibodies. Various amounts of anti-KDR antibodies were mixed with 2 ng of <sup>125</sup>I labeled VEGF<sub>165</sub> and added to a 80-90% confluent monolayer of HUVEC cells. The cells were incubated at RT for 2 h, washed and bound radioactivity was determined. Fig. 7B: Inhibition of VEGF-induced HUVEC mitogenesis by human anti-KDR antibodies. Various amounts of human anti-KDR antibodies were incubated with HUVEC cells for 1 h, followed by addition of VEGF. Cells were harvested and DNA incorporated radioactivity was determined.

[0025] Figure 8 depicts expression of KDR and VEGF by human leukemia cells. Fig. 8A: selected mRNA levels were determined by RT-PCR. Lane 1: molecular weight markers; 1000, 850, 650, 500, 400bp; Lane 2: negative control; Lane 3: HL60 cells (promyelocytic); Lane 4: HEL cells (megakaryocytic); Lane 5: U937 cells (histiocytic); Lane 6: HUVEC. Fig. 8B: Secretion of VEGF by human leukemia cells cultured with 10% FCS or in serum-free media.

[0026] Figure 9 depicts inhibition of VEGF-stimulated migration of human leukemia cells by human anti-KDR antibodies. Fig. 9A: HL60 cells. Fig. 9B: HEL cells. Fig. 9C: U937 cells.

[0027] Figure 10 depicts inhibition of leukemia advancement *in vivo* as determined by survival rates. Sublethally irradiated NOD-SCID mice were inoculated with  $2 \times 10^7$  HL60 cells and treated with various doses of IMC-1C11, IMC-2C6 or IMC-1121 via intraperitoneal injection.

#### **DETAILED DESCRIPTION OF THE INVENTION**

[0028] The present invention provides antibodies that bind specifically to an extracellular domain of VEGFR-2 (KDR). The antibodies comprise human  $V_H$  and  $V_L$  framework regions (FWs) as well as human complementary determining regions (CDRs). Preferably, the entire  $V_H$  and  $V_L$  variable domains are human or derived from human sequences. For example, a variable domain of the invention may be obtained from a peripheral blood lymphocyte that contains a rearranged variable region gene. Alternatively, variable domain portions, such as CDR and FW regions, may be derived from different human sequences. In another example, a human  $V_H$  variable domain is encoded by a human  $V_H$  gene segment and a synthetic sequence for the CDR3H region (i.e., a synthetic  $D_H-J_H$  gene segment). Likewise, a human  $V_L$  variable domain may be encoded by a human  $V_L$  gene segment and a synthetic sequence for the CDR3L region (i.e., a synthetic  $J_L$  gene segment).

[0029] Antibodies of the present invention also include those for which binding characteristics have been improved by direct mutation, methods of affinity maturation, phage display, or chain shuffling. Affinity and specificity may be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics (see, e.g., Yang et al., *J. Mol. Biol.*, 254: 392-403 (1995)). CDRs are mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that in a population of otherwise identical antigen binding sites, all twenty amino acids are found at particular positions. Alternatively, mutations are induced over a range of CDR residues by error prone PCR methods (see, e.g., Hawkins et al., *J. Mol. Biol.*, 226: 889-896 (1992)). For example, phage display vectors containing heavy and light chain variable region genes may be propagated in mutator strains of *E. coli* (see, e.g., Low et al., *J. Mol. Biol.*, 250: 359-368

(1996)). These methods of mutagenesis are illustrative of the many methods known to one of skill in the art.

[0030] The antibodies bind to KDR and neutralize activation, for example, by blocking receptor dimerization and/or VEGF binding. Antibodies of the invention can be used to neutralize VEGFR activation *in vitro* or *in vivo*, by binding to an extracellular domain of a VEGF receptor. Extracellular domains of a VEGF receptor include, for example, a ligand-binding domain on an extracellular portion of the receptor. *In vivo*, the antibodies inhibit angiogenesis, and/or reduce tumor growth,

[0031] Antibodies are proteins that recognize and bind to a specific antigen or substance. The antibodies of the present invention bind KDR at least as strongly as the natural ligand. Affinity, represented by the equilibrium constant for the dissociation of an antigen with an antibody ( $K_d$ ), measures the binding strength between an antigenic determinant and an antibody binding site. Avidity is the measure of the strength of binding between an antibody with its antigen. Avidity is related to both the affinity between an epitope with its antigen binding site on the antibody, and the valence of the antibody. Valency refers to the number of antigen binding sites which an immunoglobulin has for a particular epitope. For example, a monovalent antibody has one binding site for a particular epitope. An antigenic determinant, or epitope, is the site on an antigen at which a given antibody binds. Typical values of  $K$  are  $10^5$  to  $10^{11}$  liters/mol. Any  $K$  less than  $10^4$  liters/mol is considered to indicate binding which is nonspecific. The reciprocal of  $K$  is designated as  $K_d$ . ( $K_d$  also may be referred to as the dissociation constant.) The lesser the value of the  $K_d$ , the stronger the binding strength between an antigenic determinant and the antibody binding site.

[0032] The natural ligand of KDR is human VEGF. VEGF binds KDR with an affinity ( $K_d$ ) of about 0.93 nM. In order to hinder the binding of VEGF with KDR, an anti-KDR antibody should bind KDR at least as strongly as VEGF. In other words, the anti-KDR antibody needs to successfully compete with VEGF with respect to binding KDR. An antibody with a  $K_d$  of at most 5 nM is considered to bind as strongly as the natural ligand. The antibodies of the invention preferably bind KDR with an affinity of at most about 4 nM, more preferably with an affinity of at most about 3 nM, most preferably with an affinity of at most about 2 nM, and optimally with an affinity of at most about 1 nM. The avidity of bivalent antibodies will, of course, be greater than the affinity. Bivalent antibodies preferably

bind KDR with an avidity greater than 0.5 nM, more preferably greater than 0.25 nM, and optimally greater than 0.1 nM.

[0033] The antibodies of the invention neutralize KDR. (See Examples.) In this specification, neutralizing a receptor means diminishing and/or inactivating the intrinsic kinase activity of the receptor to transduce a signal. A reliable assay for KDR neutralization is the inhibition of receptor phosphorylation.

[0034] The present invention is not limited by any particular mechanism of KDR neutralization. The mechanism followed by one antibody is not necessarily the same as that followed by another. Some possible mechanisms include preventing binding of the VEGF ligand to the extracellular binding domain of the KDR, and preventing dimerization or oligomerization of receptors. Other mechanisms cannot, however, be ruled out.

[0035] Antibodies of the invention include, but are not limited to, naturally occurring antibodies, bivalent fragments such as  $(Fab')_2$ , monovalent fragments such as Fab, single chain antibodies, single chain Fv (scFv), single domain antibodies, multivalent single chain antibodies, diabodies, triabodies, and the like that bind specifically with antigens.

[0036] Monovalent single chain antibodies (i.e., scFv) include an antibody variable heavy-chain fragment ( $V_H$ ) linked to an antibody variable light-chain fragment ( $V_L$ ) by a peptide linker which allows the two fragments to associate to form a functional antigen binding site (see, for example U.S. Pat. No. 4,946,778 (Ladner et al.), WO 88/09344, (Huston et al.). WO 92/01047 (McCafferty et al.) describes the display of scFv fragments on the surface of soluble recombinant genetic display packages, such as bacteriophage. A single chain antibody with a linker (L) can be represented as  $V_L$ -L- $V_H$  or  $V_H$ -L- $V_L$ .

[0037] Each domain of the antibodies of this invention may be a complete antibody heavy or light chain variable domain, or it may be a functional equivalent or a mutant or derivative of a naturally occurring domain, or a synthetic domain constructed, for example, *in vitro* using a technique such as one described in WO 93/11236 (Griffiths et al.). For instance, it is possible to join together domains corresponding to antibody variable domains which are missing at least one amino acid. The important characterizing feature is the ability of each domain to associate with a complementary domain to form an antigen binding site. Accordingly, the terms "variable heavy/light chain fragment" should not be construed to exclude variants which do not have a material effect on how the invention works.

[0038] Functional equivalents of the invention include polypeptides with amino acid sequences substantially the same as the amino acid sequence of the variable or hypervariable regions of the full length KDR antibodies. "Substantially the same" amino acid sequence is defined herein as a sequence with at least 70%, preferably at least about 80%, and more preferably at least about 90% homology to another amino acid sequence, as determined by the FASTA search method in accordance with Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85, 2444-8 (1988).

[0039] Single domain antibodies have a single variable domain that is capable of efficiently binding antigen. Examples of antibodies wherein binding affinity and specificity are contributed primarily by one or the other variable domain are known in the art. See, e.g., Jeffrey, P.D. et al., *Proc. Natl. Acad. Sci. USA* 90:10310-4 (1993), which discloses an anti-digoxin antibody which binds to digoxin primarily by the antibody heavy chain. Accordingly, single antibody domains can be identified that bind well to VEGF receptors. Such antibody domains can be obtained, for example, from naturally occurring antibodies, or Fab or scFv phage display libraries. It is understood that, to make a single domain antibody from an antibody comprising a  $V_H$  and a  $V_L$  domain, certain amino acid substitutions outside the CDR regions may be desired to enhance binding, expression or solubility. For example, it may be desirable to modify amino acid residues that would otherwise be buried in the  $V_H$ - $V_L$  interface.

[0040] More recently, antibodies that are homodimers of heavy chains have been discovered in camelids (camels, dromedaries and llamas). These heavy chain antibodies are devoid of light chains and the first constant domain. (See, e.g., Muyldermans, S., 2001, *J. Biotechnol.* 74:277-302) The reduced-size antigen binding fragments are well expressed in bacteria, bind to antigen with high affinity, and are very stable. Phage display libraries of single domain antibodies (*i.e.*, having a single variable domain that can be a light chain or a heavy chain variable domain) can be produced and screened in the same manner as scFv and Fab libraries. Scaffolds for such single domain antibodies can be modified mouse or human variable domains. It is noted that single antibody domains can bind antigen in a variety of antigen binding modes. That is, the primary antibody-antigen interactions are not limited to amino acid residues corresponding to CDRs of  $V_H$ - $V_L$  containing antibodies, and consideration can be given to binding interactions outside of CDR residues when optimizing the binding characteristics of such antibodies.

[0041] Single chain antibodies lack some or all of the constant domains of the whole antibodies from which they are derived. Therefore, they may overcome some of the problems associated with the use of whole antibodies. For example, single-chain antibodies tend to be free of certain undesired interactions between heavy-chain constant regions and other biological molecules. Additionally, single-chain antibodies are considerably smaller than whole antibodies and may have greater permeability than whole antibodies, allowing single-chain antibodies to localize and bind to target antigen-binding sites more efficiently. Also, single chain antibodies can be produced on a relatively large scale in prokaryotic cells, thus facilitating their production. Furthermore, the relatively small size of single-chain antibodies makes them less likely to provoke an unwanted immune response in a recipient than whole antibodies.

[0042] The peptide linkers used to produce the single chain antibodies may be flexible peptides selected to assure that the proper three-dimensional folding of the  $V_L$  and  $V_H$  domains may occur once they are linked so as to maintain the target molecule binding-specificity of the full length anti-KDR antibody. Generally, the carboxyl terminus of the  $V_L$  or  $V_H$  sequence may be covalently linked by such a peptide linker to the amino acid terminus of a complementary  $V_H$  or  $V_L$  sequence. The linker is generally 10 to 50 amino acid residues. Preferably, the linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid residues. Most preferably is a linker of 15 to 25 amino acid residues. An example of such linker peptides include  $(\text{Gly-Gly-Gly-Gly-Ser})_3$ .

[0043] Single chain antibodies, each having one  $V_H$  and one  $V_L$  domain covalently linked by a first peptide linker, can be covalently linked by at least one more peptide linker to form a multivalent single chain antibody. Multivalent single chain antibodies allow for the construction of antibody fragments which have the specificity and avidity of whole antibodies, but lack the constant regions of the full length antibodies.

[0044] Multivalent antibodies may be monospecific or multispecific. The term specificity refers to the number of different types of antigenic determinants to which a particular antibody can bind. If the antibody binds to only one type of antigenic determinant, the antibody is monospecific. If the antibody binds to different types of antigenic determinants then the antibody is multispecific.

[0045] For example, a bispecific multivalent single chain antibody allows for the recognition of two different types of epitopes. The epitopes may both be on KDR. Alternatively, one epitope may be on KDR, and the other epitope may be on another antigen.

[0046] Each chain of a multivalent single chain antibody includes a variable light-chain fragment and a variable heavy-chain fragment, and is linked by a peptide linker to at least one other chain. The peptide linker is composed of at least fifteen amino acid residues. The maximum number of amino acid residues is about one hundred. In a preferred embodiment, the number of  $V_L$  and  $V_H$  domains is equivalent. Preferably, the peptide linker ( $L_1$ ) joining the  $V_H$  and  $V_L$  domains to form a chain and the peptide linker ( $L_2$ ) joining two or more chains to form a multivalent scFv have substantially the same amino acid sequence.

[0047] For example, a bivalent single chain antibody can be represented as follows:  $V_L-L_1-V_H-L_2-V_L-L_1-V_H$ ; or  $V_L-L_1-V_H-L_2-V_H-L_1-V_H$ ; or  $V_H-L_1-V_L-L_2-V_H-L_1-V_L$ ; or  $V_H-L_1-V_L-L_2-V_L-L_1-V_H$ .

[0048] Multivalent single chain antibodies which are trivalent or greater have one or more antibody fragments joined to a bivalent single chain antibody by additional peptide linkers. One example of a trivalent single chain antibody is:

$V_L-L_1-V_H-L_2-V_L-L_1-V_H-L_2-V_L-L_1-V_H$ .

[0049] Two single chain antibodies can be combined to form a diabody, also known as a bivalent dimer. Diabodies have two chains and two binding sites, and may be monospecific or bispecific. Each chain of the diabody includes a  $V_H$  domain connected to a  $V_L$  domain. The domains are connected with linkers that are short enough to prevent pairing between domains on the same chain, thus driving the pairing between complementary domains on different chains to recreate the two antigen-binding sites. Accordingly, one chain of a bispecific diabody comprises  $V_H$  of a first specificity and  $V_L$  of a second specificity, whereas the second chain comprises  $V_H$  of the second specificity and  $V_L$  of the first specificity. The peptide linker includes at least five amino acid residues and no more than ten amino acid residues, e.g. (Gly-Gly-Gly-Gly-Ser), (Gly-Gly-Gly-Gly-Ser)<sub>2</sub>. (SEQ ID NO:19.) The diabody structure is rigid and compact. The antigen-binding sites are at opposite ends of the molecule.

[0050] Three single chain antibodies can be combined to form triabodies, also known as trivalent trimers. Triabodies are constructed with the amino acid terminus of a  $V_L$  or  $V_H$  domain directly fused to the carboxyl terminus of a  $V_L$  or  $V_H$  domain, i.e., without any

linker sequence. The triabody has three Fv heads with the polypeptides arranged in a cyclic, head-to-tail fashion. A possible conformation of the triabody is planar with the three binding sites located in a plane at an angle of 120 degrees from one another. Triabodies may be monospecific, bispecific or trispecific.

[0051] Preferably the antibodies of this invention contain all six complementarity determining regions of the whole antibody, although antibodies containing fewer than all of such regions, such as three, four or five CDRs, are also functional.

[0052] To minimize the immunogenicity of antibodies that bind to VEGF receptors, the present invention provides antibodies which comprise human variable and constant domain sequences. The antibodies are derived from a human source and bind to an extracellular domain of KDR and neutralize activation of the receptor. DNA encoding human antibodies may be prepared by recombining DNA encoding human constant regions and DNA encoding variable regions derived from humans. For example, antibodies of the invention can be obtained by screening libraries consisting of combinations of human light chain and heavy chain variable domains. The nucleic acids from which the antibodies are expressed can be somatically mutated, or be germline sequences derived from naive B cells.

[0053] DNA encoding human antibodies may be prepared by recombining DNA encoding human constant regions and variable regions, other than the CDRs, derived substantially or exclusively from the corresponding human antibody regions and DNA encoding CDRs derived from a human.

[0054] Suitable sources of DNAs that encode fragments of antibodies include any cell, such as hybridomas and spleen cells, that express the full length antibody. Another source is single chain antibodies produced from a phage display library as is known in the art.

[0055] The antibodies of this invention may be or may combine members of any immunoglobulin class, such as IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof.

[0056] The protein used to identify VEGFR binding antibodies of the invention is usually KDR, and is normally limited to the extracellular domain of KDR. The KDR extracellular domain may be free or conjugated to another molecule.

[0057] In the examples below high affinity anti-KDR antibodies, which block VEGF binding to KDR, were isolated from a phage display library constructed from human heavy chain and light chain variable region genes. Over 90% of recovered clones after three rounds of selection are specific to KDR. The binding affinities for KDR of the screened Fabs

are in the nM range, which are as high as those of several bivalent anti-KDR monoclonal antibodies produced using hybridoma technology.

[0058] The antibodies of this invention may be fused to additional amino acid residues. Such residues may be a peptide tag, perhaps to facilitate isolation, or they may be a signal sequence for secretion of the polypeptide from a host cell upon synthesis. Suitably, secretory leader peptides are used, being amino acids joined to the N-terminal end of a polypeptide to direct movement of the polypeptide out of the cytosol.

[0059] The present invention also provides nucleic acids which comprise a sequence encoding a polypeptide according to the invention, and diverse repertoires of such nucleic acid.

[0060] Antibodies of the invention neutralize activation of KDR. One measure of KDR neutralization is inhibition of the tyrosine kinase activity of the receptor. Tyrosine kinase inhibition can be determined using well-known methods. The antibodies of the present invention generally cause inhibition or regulation of phosphorylation events. Accordingly, phosphorylation assays are useful in determining antibodies useful in the context of the present invention. Tyrosine kinase inhibition may be determined by measuring the autophosphorylation level of recombinant kinase receptor, and/or phosphorylation of natural or synthetic substrates. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., *J. Pharmacol. Exp. Thera.*, 283: 1433-44 (1997) and Batley et al., *Life Sci.*, 62: 143-50 (1998).

[0061] In addition, methods for detection of protein expression can be utilized, wherein the proteins being measured are regulated by KDR tyrosine kinase activity. These methods include immunohistochemistry (IHC) for detection of protein expression, fluorescence in situ hybridization (FISH) for detection of gene amplification, competitive radioligand binding assays, solid matrix blotting techniques, such as Northern and Southern blots, reverse transcriptase polymerase chain reaction (RT-PCR) and ELISA. See, e.g., Grandis et al., *Cancer*, 78:1284-92. (1996); Shimizu et al., *Japan J. Cancer Res.*, 85:567-71 (1994); Sauter et al., *Am. J. Path.*, 148:1047-53 (1996); Collins, *Glia*, 15:289-96 (1995); Radinsky et al., *Clin. Cancer Res.*, 1:19-31 (1995); Petrides et al., *Cancer Res.*, 50:3934-39 (1990); Hoffmann et al., *Anticancer Res.*, 17:4419-26 (1997); Wikstrand et al., *Cancer Res.*, 55:3140-48 (1995).

[0062] *In vivo* assays can also be utilized. For example, receptor tyrosine kinase inhibition can be observed by mitogenic assays using cell lines stimulated with receptor ligand in the presence and absence of inhibitor. For example, HUVEC cells (ATCC) stimulated with VEGF can be used to assay VEGFR inhibition. Another method involves testing for inhibition of growth of VEGF-expressing tumor cells, using for example, human tumor cells injected into a mouse. See, U.S. Patent No. 6,365,157 (Rockwell et al.).

[0063] In the methods of the present invention, a therapeutically effective amount of an antibody of the invention is administered to a mammal in need thereof. The term "administering" as used herein means delivering the antibodies of the present invention to a mammal by any method that may achieve the result sought. They may be administered, for example, intravenously or intramuscularly. Although human antibodies of the invention are particularly useful for administration to humans, they may be administered to other mammals as well. The term "mammal" as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals. "Therapeutically effective amount" means an amount of antibody of the present invention that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase activity.

[0064] While not intended to be bound to any particular mechanism, the diseases and conditions which may be treated or prevented by the present methods include, for example, those in which pathogenic angiogenesis or tumor growth is stimulated through a VEGFR paracrine and/or autocrine loop.

[0065] Neutralization of activation of a VEGF receptor in endothelial or non-endothelial cells, such as tumor cells, may be performed *in vitro* or *in vivo*. Neutralizing VEGF activation of a VEGF receptor in a sample of VEGF-receptor expressing cells comprises contacting the cells with an antagonist, e.g., an antibody, of the invention. The cells are contacted *in vitro* with the antagonist, e.g., the antibody, before, simultaneously with, or after, adding VEGF to the cell sample.

[0066] *In vivo*, an antibody of the invention is contacted with a VEGF receptor by administration to a mammal, preferably a human. An *in vivo* neutralization method is useful for inhibiting tumor growth, angiogenesis associated with tumor growth, or other pathologic condition associated with angiogenesis, in a mammal. Accordingly, the antibodies of the invention are anti-angiogenic and anti-tumor immunotherapeutic agents.

[0067] Tumors which may be treated include primary tumors and metastatic tumors, as well as refractory tumors. Refractory tumors include tumors that fail to respond or are resistant to treatment with chemotherapeutic agents alone, antibodies alone, radiation alone or combinations thereof. Refractory tumors also encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued.

[0068] Antibodies of the present invention are useful for treating tumors that express VEGF receptors, especially KDR. Such tumors are characteristically sensitive to VEGF present in their environment, and may further produce and be stimulated by VEGF in an autocrine stimulatory loop. The method is therefore effective for treating a solid or non-solid tumor that is not vascularized, or is not yet substantially vascularized. Examples of solid tumors which may be accordingly treated include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma. Some examples of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. Other examples include Kaposi's sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma. Examples of vascularized skin cancers for which the antagonists of this invention are effective include squamous cell carcinoma, basal cell carcinoma and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes.

[0069] Examples of non-solid tumors include leukemia, multiple myeloma and lymphoma. Some examples of leukemias include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), erythrocytic leukemia or monocytic leukemia. Some examples of lymphomas include Hodgkin's and non-Hodgkin's lymphoma.

[0070] Experimental results described below demonstrate that antibodies of the invention specifically block VEGF induced stimulation of KDR (VEGFR-2) in leukemia cells. *In vivo* studies also described below show that the antibodies were able to significantly inhibit tumor growth in nude mice.

[0071] A cocktail of VEGF receptor antagonists, e.g., monoclonal antibodies, provides an especially efficient treatment for inhibiting the growth of tumor cells. The cocktail may include non-antibody VEGFR antagonists and may have as few as 2, 3 or 4 receptor antagonists, and as many as 6, 8 or 10.

[0072] In another aspect of the invention, anti-KDR antibodies are used to inhibit angiogenesis. VEGFR stimulation of vascular endothelium is associated with angiogenic diseases and vascularization of tumors. Typically, vascular endothelium is stimulated in a paracrine fashion by VEGF from other sources (e.g., tumor cells).

[0073] Accordingly, the human anti-KDR antibodies are effective for treating subjects with vascularized tumors or neoplasms or angiogenic diseases. Such tumors and neoplasms include, for example, malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and highly vascular tumors and neoplasms. Cancers that may be treated by the methods of the present invention include, for example, cancers of the brain, genitourinary tract, lymphatic system, stomach, renal, colon, larynx and lung and bone. Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. The method is also used for treatment of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes. Other cancers that can be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, and leiomyosarcoma.

[0074] A further aspect of the present invention includes methods of treating or preventing pathologic conditions characterized by excessive angiogenesis, involving, for example, vascularization and/or inflammation, such as atherosclerosis, rheumatoid arthritis (RA), neovascular glaucoma, proliferative retinopathy including proliferative diabetic retinopathy, macular degeneration, hemangiomas, angiofibromas, and psoriasis. Other non-limiting examples of non-neoplastic angiogenic disease are retinopathy of prematurity (retrolental fibroplastic), corneal graft rejection, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary

cirrhosis, acute pancreatitis, allograft rejection, allergic inflammation, contact dermatitis and delayed hypersensitivity reactions, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, cognition defects induced by neuronal inflammation, Osler-Weber syndrome, restinosis, and fungal, parasitic and viral infections, including cytomegaloviral infections.

[0075] The identification of such disease is well within the ability and knowledge of one skilled in the art. For example, human individuals who are either suffering from a clinically significant neoplastic or angiogenic disease or who are at risk of developing clinically significant symptoms are suitable for administration of the present VEGF receptor antibodies. A clinician skilled in the art can readily determine, for example, by the use of clinical tests, physical examination and medical/family history, if an individual is a candidate for such treatment.

[76] Moreover, included within the scope of the present invention is use of the present antibodies *in vivo* and *in vitro* for investigative or diagnostic methods, which are well known in the art.

[77] The present anti-KDR antibodies can be administered for therapeutic treatments to a patient suffering from a tumor or angiogenesis associated pathologic condition in an amount sufficient to prevent, inhibit, or reduce the progression of the tumor or pathologic condition. Progression includes, e.g., the growth, invasiveness, metastases and/or recurrence of the tumor or pathologic condition. An amount adequate to accomplish this is defined as a therapeutically effective dose. Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system. Dosing schedules will also vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the treating physician and the patient's condition. It should be noted, however, that the present invention is not limited to any particular dose.

[78] In an embodiment of the invention, anti-KDR antibodies can be administered in combination with one or more other antineoplastic agents. For examples of combination therapies, see, e.g., U.S. Patent No. 6,217,866 (Schlessinger et al.) (Anti-EGFR antibodies in combination with antineoplastic agents); WO 99/60023 (Waksal et al.) (Anti-EGFR antibodies in combination with radiation). Any suitable antineoplastic agent can be used, such as a chemotherapeutic agent or radiation. Examples of chemotherapeutic agents include, but are not limited to, cisplatin, doxorubicin, paclitaxel, irinotecan (CPT-11), topotecan or a

combination thereof. When the antineoplastic agent is radiation, the source of the radiation can be either external (external beam radiation therapy – EBRT) or internal (brachytherapy – BT) to the patient being treated. The dose of antineoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose.

[79] Further, anti-KDR antibodies of the invention may be administered with antibodies that neutralize other receptors involved in tumor growth or angiogenesis. One example of such a receptor is the VEGFR-1/Flt-1 receptor. In an embodiment of the invention, an anti-KDR antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-1. Particularly preferred are antigen-binding proteins that bind to the extracellular domain of VEGFR-1 and block binding by one or both of its ligands, VEGF and PIGF, and/or neutralize VEGF-induced or PI GF-induced activation of VEGFR-1. For example, mAb 6.12 is a scFv that binds to soluble and cell surface-expressed VEGFR-1. ScFv 6.12 comprises the  $V_L$  and  $V_H$  domains of mouse monoclonal antibody mAb 6.12. A hybridoma cell line producing mAb 6.12 has been deposited as ATCC number PTA-3344 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the regulations thereunder (Budapest Treaty).

[80] Another example of such a receptor is EGFR. In an embodiment of the present invention, an anti-KDR antibody is used in combination with an EGFR antagonist. An EGFR antagonist can be an antibody that binds to EGFR or a ligand of EGFR and inhibits binding of EGFR to its ligand. Ligands for EGFR include, for example, EGF, TGF- $\alpha$  amphiregulin, heparin-binding EGF (HB-EGF) and betarecullulin. EGF and TGF- $\alpha$  are thought to be the main endogenous ligands that result in EGFR-mediated stimulation, although TGF- $\alpha$  has been shown to be more potent in promoting angiogenesis. It should be appreciated that the EGFR antagonist can bind externally to the extracellular portion of EGFR, which may or may not inhibit binding of the ligand, or internally to the tyrosine kinase domain. Examples of EGFR antagonists that bind EGFR include, without limitation, biological molecules, such as antibodies (and functional equivalents thereof) specific for EGFR, and small molecules, such as synthetic kinase inhibitors that act directly on the cytoplasmic domain of EGFR.

[81] Other examples of growth factor receptors involved in tumorigenesis are the receptors for platelet-derived growth factor (PDGFR), insulin-like growth factor (IGFR), nerve growth factor (NGFR), and fibroblast growth factor (FGFR).

[82] In an additional alternative embodiment, the VEGFR antagonist can be administered in combination with one or more suitable adjuvants, such as, for example, cytokines (IL-10 and IL-13, for example) or other immune stimulators. *See, e.g., Larrivée et al., supra.* It should be appreciated, however, that administration of only an anti-KDR antibody is sufficient to prevent, inhibit, or reduce the progression of the tumor in a therapeutically effective manner.

[83] In a combination therapy, the anti-KDR antibody is administered before, during, or after commencing therapy with another agent, as well as any combination thereof, *i.e.*, before and during, before and after, during and after, or before, during and after commencing the antineoplastic agent therapy. For example, the anti-KDR antibody may be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy.

[84] In the present invention, any suitable method or route can be used to administer anti-KDR antibodies of the invention, and optionally, to coadminister antineoplastic agents and/or antagonists of other receptors. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration. The dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.

[85] It is noted that an anti-KDR antibody of the invention can be administered as a conjugate, which binds specifically to the receptor and delivers a toxic, lethal payload following ligand-toxin internalization.

[86] It is understood that the anti-KDR antibodies of the invention, where used in a mammal for the purpose of prophylaxis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of

auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the binding proteins. The compositions of the injection may, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.

[87] The present invention also includes kits for inhibiting tumor growth and/or angiogenesis comprising a therapeutically effective amount of a human anti-KDR antibody. The kits can further contain any suitable antagonist of, for example, another growth factor receptor involved in tumorigenesis or angiogenesis (e.g., VEGFR-1/Flt-1, EGFR, PDGFR, IGFR, NGFR, FGFR, etc, as described above). Alternatively, or in addition, the kits of the present invention can further comprise an antineoplastic agent. Examples of suitable antineoplastic agents in the context of the present invention have been described herein. The kits of the present invention can further comprise an adjuvant, examples have also been described above.

[88] In another aspect of the invention, an anti-KDR antibody of the invention can be chemically or biosynthetically linked to one or more antineoplastic or antiangiogenic agents.

[89] The invention further contemplates anti-KDR antibodies to which target or reporter moieties are linked. Target moieties are first members of binding pairs. Antineoplastic agents, for example, are conjugated to second members of such pairs and are thereby directed to the site where the anti-KDR antibody is bound. A common example of such a binding pair is adivin and biotin. In a preferred embodiment, biotin is conjugated to an anti-KDR antibody, and thereby provides a target for an antineoplastic agent or other moiety which is conjugated to avidin or streptavidin. Alternatively, biotin or another such moiety is linked to an anti-KDR antibody of the invention and used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.

[90] Accordingly, the present receptor antagonists thus can be used *in vivo* and *in vitro* for investigative, diagnostic, prophylactic, or treatment methods, which are well known in the art. Of course, it is to be understood and expected that variations in the principles of invention herein disclosed can be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.

[91] All references mentioned herein are incorporated in their entirety.

**EXAMPLES**

[0092] The Examples which follow are set forth to aid in understanding the invention but are not intended to, and should not be construed to, limit its scope in any way. The Examples do not include detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and plasmids, or the introduction of plasmids into host cells. Such methods are well known to those of ordinary skill in the art and are described in numerous publications including Sambrook, J., and Russell, D.W. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press.

**Example I. Production of human Fab****Example I(a). Proteins and Cell Lines.**

[0093] Primary-cultured HUVEC were obtained from Dr. S. Rafii at Cornell Medical Center, New York, and maintained in EBM-2 medium (Clonetics, Walkersville, MD) at 37°C, 5% CO<sub>2</sub>. The soluble fusion proteins, KDR-alkaline phosphatase (AP), its immunoglobulin (Ig) domain-deletion variants, and Flk-1-AP, were expressed in stably transfected NIH 3T3 and purified from cell culture supernatants by affinity chromatography using immobilized monoclonal antibody to AP as described by Lu et al., *J. Biol. Chem.* 275: 14321-30 (2000). VEGF<sub>165</sub> protein was expressed in baculovirus and purified following the procedures described in Zhu et al., *Cancer Res.* 58: 3209-14 (1998). The leukemia cell lines, HL60 and HEL, were maintained in RPMI containing 10% fetal calf serum.

**Example I(b). Phage ELISA**

[0094] Individual TG1 clones were picked and grown at 37°C in 96 well plates and rescued with M13K07 helper phage as described above. The amplified phage preparation was blocked with 1/6 volume of 18% milk/PBS at RT for 1 h and added to Maxi-sorp 96-well microtiter plates (Nunc) coated with KDR-AP or AP (1 µg/ml x 100 µl). After incubation at RT for 1 h the plates were washed 3 times with PBST and incubated with a rabbit anti-M13 phage-HRP conjugate (Amersham Pharmacia Biotech, Piscataway, NJ). The plates were washed 5 times, TMB peroxidase substrate (KPL, Gaithersburg, MD) added, and the absorbance at 450 nm read using a microplate reader (Molecular Devices, Sunnyvale, CA).

**Example I(c). DNA BstNI pattern analysis and nucleotide sequencing.**

[0095] The diversity of the anti-KDR Fab clones after each round of selection was analyzed by restriction enzyme digestion patterns (i.e., DNA fingerprints). The Fab gene insert of individual clones was PCR amplified using primers: PUC19 reverse, 5' AGCGGATAACAATTTCACACAGG 3'; and fdtet seq, 5' GTCGTCTTCAGACGTTAGT 3'. The amplified product was digested with a frequent-cutting enzyme, *Bst*N I, and analyzed on a 3% agarose gel. DNA sequences of representative clones from each digestion pattern were determined by dideoxynucleotide sequencing.

**Example I(d). *Expression and purification of soluble Fab fragments.***

[0096] Plasmids of individual clones were used to transform a nonsuppressor *E. coli* host HB2151. Expression of the Fab fragments in HB2151 was induced by culturing the cells in 2YTA medium containing 1 mM isopropyl-1-thio- $\beta$ -D-galactopyranoside (IPTG, Sigma) at 30°C. A periplasmic extract of the cells was prepared by resuspending the cell pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM NaCl, 1 mM EDTA and 0.1 mM PMSF, followed by incubation at 4°C with gentle shaking for 1 h. After centrifugation at 15,000 rpm for 15 min, the soluble Fab protein was purified from the supernatant by affinity chromatography using a Protein G column followed the manufacturer's protocol (Amersham Pharmacia Biotech).

**Example I(e). *Selection of human anti-KDR Fab from phage display library.***

[0097] A large human Fab phage display library containing  $3.7 \times 10^{10}$  clones (DeHaard et al., *J. Biol. Chem.* 274: 18218-30 (1999)) was used for the selection. The library consists of PCR-amplified antibody variable light chain genes and variable heavy chain genes fused to human constant light chain genes ( $\kappa$  and  $\lambda$ ) and DNA encoding the IgG1 heavy chain C<sub>H</sub>1 domain, respectively. Both heavy and light chain constructs are preceded by a signal sequence - *pelB* for the light chain and gene III signal sequence for the heavy chain. Heavy chain constructs further encode a portion of the gene III protein for phage display, a hexahistidine tag, and an 11 amino-acid-long c-myc tag, followed by an amber codon (TAG). The hexahistidine and c-myc tags can be used for purification or detection. The amber codon allows for phage display using suppressor hosts (such as TG1 cells) or production of Fab fragments in soluble form when transformed into a nonsuppressor host (such as HB2151 cells).

[0098] The library stock was grown to log phase, rescued with M13-KO7 helper phage and amplified overnight in 2YTAK medium (2YT containing 100  $\mu$ g/ml of ampicillin

and 50  $\mu$ g/ml of kanamycin) at 30°C. The phage preparation was precipitated in 4% PEG/0.5M NaCl, resuspended in 3% fat-free milk/PBS containing 500  $\mu$ g/ml of AP protein and incubated at 37°C for 1 h to capture phage displaying anti-AP Fab fragments and to block other nonspecific binding.

[0099] KDR-AP (10  $\mu$ g/ml in PBS) coated Maxisorp Star tubes (Nunc, Roskilde, Denmark) were first blocked with 3% milk/PBS at 37°C for 1 h, and then incubated with the phage preparation at RT for 1 h. The tubes were washed 10 times with PBST (PBS containing 0.1% Tween-20) followed by 10 times with PBS. Bound phage were eluted at RT for 10 min with 1 ml of a freshly prepared solution of 100 mM triethylamine (Sigma, St. Louis, MO). The eluted phage were incubated with 10 ml of mid-log phase TG1 cells at 37°C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted and plated onto several large 2YTAG plates and incubated overnight at 30°C. All the colonies grown on the plates were scraped into 3 to 5 ml of 2YTA medium, mixed with glycerol (10% final concentration), aliquoted and stored at -70°C. For the next round selection, 100  $\mu$ l of the phage stock was added to 25 ml of 2YTAG medium and grown to mid-log phase. The culture was rescued with M13K07 helper phage, amplified, precipitated, and used for selection followed the procedure described above, with reduced concentrations of KDR-AP immobilized on the immunotube and increased number of washes after the binding process.

[0100] A total of three rounds of selection were performed on immobilized KDR, with varying protein concentrations and number of washings after the initial binding process. After each round selection, 93 clones were randomly picked and tested by phage ELISA for binding to KDR. Seventy out of the 93 clones (75%) picked after the second selection, and greater than 90% of the recovered clones after the third selection were positive in KDR binding, suggesting a high efficiency of the selection process. DNA segments encoding the Fab from all the 70 binders identified in the second selection were amplified, digested with *Bst*N I, and compared for fingerprint patterns. A total of 42 different patterns were observed, indicating an excellent diversity of the isolated anti-KDR Fab. Cross-reactivity examination demonstrated that 19 out of the 42 antibodies were specific KDR-binders, whereas the rest 23 antibodies bound to both KDR and its murine homologue, Flk-1. Further selection was achieved with a competitive VEGF-binding assay in which the binding of soluble KDR to immobilized VEGF in the presence or absence of the anti-KDR Fab fragments was determined. The assay identified four Fab clones that were capable of blocking the binding

between VEGF and KDR. Three were KDR-specific binders and one cross-reacted with Flk-1. DNA fingerprinting and sequencing analysis confirmed that all four KDR/VEGF blocking antibodies were different (Fig. 1A) with unique DNA and amino acid sequences.

[0101] The amino acid sequences for CDR1, CDR2 and CDR3 of  $V_H$  and  $V_L$  for the four clones are given in Table 1.

Table 1 - CDR sequences of selected KDR-binding human Fabs			
Clone	CDR1	CDR2	CDR3
<b>Light Chain</b>			
D2C6	RASQSVSSYLA (SEQ ID NO:1)	DSSNRAT (SEQ ID NO:2)	LQHNTFPPT (SEQ ID NO:3)
D2H2	RASQGISSRLA (SEQ ID NO:4)	AASSLQT (SEQ ID NO:5)	QQANRFPPT (SEQ ID NO:6)
D1H4	AGTTTDLTYYDLVS (SEQ ID NO:7)	DGNKRPS (SEQ ID NO:8)	NSYVSSRFYV (SEQ ID NO:9)
D1F7	SGSTSNIKTNTAN (SEQ ID NO:10)	NNNQRPS (SEQ ID NO:11)	AAWDDSLNGHWV (SEQ ID NO:12)
<b>Heavy Chain</b>			
D2C6	GFTFSSYSMN (SEQ ID NO:13)	SISSSSSYIYYADSVKG (SEQ ID NO:14)	VTDAFDI (SEQ ID NO:15)
D2H2	GFTFSSYSMN (SEQ ID NO:13)	SISSSSSYIYYADSVKG (SEQ ID NO:14)	VTDAFDI (SEQ ID NO:15)
D1H4	GFTFSSYSMN (SEQ ID NO:13)	SISSSSSYIYYADSVKG (SEQ ID NO:14)	VTDAFDI (SEQ ID NO:15)
D1F7	GGTFSSSYAIS (SEQ ID NO:16)	GGIIPIFGTANYAQKFQG (SEQ ID NO:17)	GYDYYDSSGVASPDFY (SEQ ID NO:18)

Complete sequences for the  $V_H$  and  $V_L$  chains are presented in the Sequence Listing. For D1F7, the nucleotide and amino acid sequences for  $V_H$  are represented by SEQ ID NOS:19 and 20 respectively, and the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 21 and 22.

[0102] For D2C6, the nucleotide and amino acid sequences for  $V_H$  are represented by SEQ ID NOS: 23 and 24 respectively, and the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 25 and 26.

[0103] For D2H2, the nucleotide and amino acid sequences for  $V_H$  are represented by SEQ ID NOS: 30 and 31 respectively, and the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 32 and 33.

[0104] For D1H4, the nucleotide and amino acid sequences for  $V_H$  are represented by SEQ ID NOS: 27 and 24 respectively, and the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 28 and 29.

[0105] A second library was created combining the single heavy chain of D2C6 with a diverse population of light chains derived from the original library. Ten additional Fabs were identified, designated SA1, SA3, SB10, SB5, SC7, SD2, SD5, SF2, SF7, and 1121. The nucleotide and amino acid sequences for  $V_L$  of the ten Fabs are represented as follows. For SA1, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 34 and 35. For SA3, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 36 and 37. For SB10, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 38 and 39. For SB5, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 40 and 41. For SC7, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 42 and 43. For SD2, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 44 and 45. For SD5, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 46 and 47. For SF2, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 48 and 49. For SF7, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 50 and 51. For 1121, the nucleotide and amino acid sequences for  $V_L$  are represented by SEQ ID NOS: 52 and 53.

[0106] The  $V_L$  CDR sequences are presented in Table 2.

**Table 2 - Light chain CDR sequences of KDR-binding human Fab**

Clone	CDR1	CDR2	CDR3
SA1	TGSHSNFGAGTDV (SEQ ID NO:54)	GDSNRPS (SEQ ID NO:55)	QSYDYGLRGWV (SEQ ID NO:56)
SA3	RASQNIINNYLN (SEQ ID NO:57)	AASTLQS (SEQ ID NO:58)	QQYSRYPPT (SEQ ID NO:59)
SB10	TGSSTDVGNYNYIS (SEQ ID NO:60)	DVTSRPS (SEQ ID NO:61)	NSYSATDTLV (SEQ ID NO:62)
SB5	TGQSSNIGADYDVH (SEQ ID NO:63)	GHNNRPS (SEQ ID NO:64)	QSYDSSLGGLV (SEQ ID NO:65)
SC7	RASQDISSWLA (SEQ ID NO:66)	AASLLQS (SEQ ID NO:67)	QQADSFPPPT (SEQ ID NO:68)
SD2	RASQSIKRWLA (SEQ ID NO:69)	AASTLQS (SEQ ID NO:70)	QQANSFPPT (SEQ ID NO:71)
SD5	SGSRSNIGAHYEVQ (SEQ ID NO:72)	GDTNRPS (SEQ ID NO:73)	QSYDTSLRGPV (SEQ ID NO:74)
SF2	TGSSSNIGTGYDVH (SEQ ID NO:75)	AYTNRPS (SEQ ID NO:76)	QSFDDSLNGLV (SEQ ID NO:77)
SF7	TGSHSNFGAGTDVH (SEQ ID NO:78)	GDTHRPS (SEQ ID NO:79)	QSYDYGLRGWV (SEQ ID NO:80)
1121	RASQGIDNWLG (SEQ ID NO:81)	DASNLDT (SEQ ID NO:82)	QQAKA FPPT (SEQ ID NO:83)

**Example II. Assays****Example II(a). Quantitative KDR binding and blocking of KDR/VEGF interaction.**

[0107] In a direct binding assay, various amounts of soluble Fab proteins were added to KDR-coated 96-well Maxi-sorp microtiter plates and incubated at RT for 1 h, after which the plates were washed 3 times with PBST. The plates were then incubated at RT for 1 h with 100  $\mu$ l of a rabbit anti-human Fab antibody-HRP conjugate (Jackson ImmunoResearch Laboratory Inc., West Grove, PA). The plates were washed and developed following the procedure described above for the phage ELISA. In a competitive KDR/VEGF blocking assay, various amounts of Fab proteins were mixed with a fixed amount of KDR-AP

(100 ng) and incubated at RT for 1 h. The mixtures were then transferred to 96-well microtiter plates precoated with VEGF<sub>165</sub> (200 ng/well) and incubated at RT for an additional 2 h, after which the plates were washed 5 times and the substrate for AP (p-nitrophenyl phosphate, Sigma) was added. Absorbance at 405nm was measured to quantify the bound KDR-AP molecules (8). IC<sub>50</sub>, *i.e.*, the Fab protein concentration required for 50% inhibition of KDR binding to VEGF, was then calculated.

[0108] The four VEGF-blocking clones (D2C6, D2H2, D1H4, D1F7) were expressed as soluble Fab and purified from periplasmic extracts of *E. coli* by Protein G affinity chromatography. The yield of purified Fab proteins of these clones ranged from 60 to 400  $\mu$ g / liter culture. SDS-PAGE analysis of each purified Fab preparation yielded a single protein band with expected molecular size (Fig. 1B).

[0109] Fig. 2 shows the dose-dependent binding of the anti-KDR Fab fragments to immobilized receptor as assayed by a direct binding ELISA. Clone D2C6 and D2H2 are more efficient binders, followed by clone D1H4 and D1F7. All four Fabs also block KDR binding to immobilized VEGF (Fig. 2B). The antibody concentrations required for 50% of inhibition of KDR binding to VEGF are approximately 2 nM for clones D2C6, D2H2, and D1H4 and 20 nM for clone D1F7. Only clone D1F7 blocks VEGF from binding to Flk-1 (Fig. 2C), with an IC<sub>50</sub> of approximately 15 nM.

**Example II(b). BIACore analysis of the soluble scFv**

[0110] The binding kinetics of soluble Fab proteins to KDR were measured by surface plasmon resonance using a BIACore biosensor (Pharmacia Biosensor). KDR-AP fusion protein was immobilized onto a sensor chip and soluble Fab proteins were injected at concentrations ranging from 1.5 nM to 100 nM. Sensorgrams were obtained at each concentration and were evaluated using a program, BIA Evaluation 2.0, to determine the rate constants *kon* and *koff*. *Kd* was calculated from the ratio of rate constants *koff/kon*.

[0111] All three KDR-specific Fab fragments bind to immobilized receptor with *Kd* of 2 to 4 nM (Table 3). The cross-reactive clone, D1F7, has a *Kd* of 45 nM, which is about 10- to 15-fold weaker than those of the KDR-specific clones. It is noteworthy that, although the overall *Kd* for the three KDR-specific Fab fragments are similar, the individual binding kinetics, *i.e.*, the *kon* and *koff*, for these antibodies are quite different, *e.g.*, D2C6 possesses the fastest on-rate, while D1H4 has the slowest off-rate (Table 3).

**Table 3 - Binding kinetics of the four neutralizing human anti-KDR Fab fragments**

Clone	<i>kon</i> ( $10^4$ M $^{-1}$ S $^{-1}$ )	<i>koff</i> ( $10^4$ S $^{-1}$ )	Kd (nM)
Hu-2C6 Fab	$27.3 \pm 8.6^*$	$5.38 \pm 0.54$	1.97
Hu-2H2 Fab	$12.4 \pm 2.9$	$4.87 \pm 0.18$	3.93
Hu-1H4 Fab	$5.55 \pm 0.59$	$1.53 \pm 0.22$	2.76
Hu-1F7 Fab	$4.14 \pm 1.21$	$18.7 \pm 2.12$	45.2

\* All numbers are determined by BIAcore analysis and represent the mean  $\pm$  SE from at least three separate determinations.

**Example II(c). Binding epitope mapping**

[0112] The production of KDR extracellular Ig-like domain deletion variants has been previously described (Lu et al. (2000)). In an epitope-mapping assay, full length KDR-AP, Ap fusions of two KDR Ig-domain deletion variants, and Flk-1-AP were first immobilized onto a 96-well plate (Nunc) using a rabbit anti-AP antibody (DAKO-immunoglobulins, Glostrup, Denmark) as the capture reagent. The plate was then incubated with various anti-KDR Fab proteins at RT for 1 h, followed by incubation with a rabbit anti-human Fab antibody-HRP conjugate. The plate was washed and developed as described above.

[0113] The binding epitopes of the anti-KDR Fab fragments were mapped using the full-length KDR and two KDR Ig domain-deletion variants. KDR(1-3) is a KDR variant containing the first three N-terminal Ig domains. KDR(3) is a variant containing only the third Ig domain. As shown in Fig. 3, clones D2C6 and D1H4 bind equally well to KDR, KDR(1-3) and KDR(3), thus locating their binding epitope(s) within Ig domain 3. Clones D2H2 and D1F7 bind much more efficiently to full-length KDR and KDR(1-3), indicating a broader binding epitope(s) within KDR Ig domains 1 to 3. Only clone D1F7 cross-reacts with Flk-1.

**Example II(d). Anti-mitogenic assay.**

[0114] HUVEC ( $5 \times 10^3$  cells/well) were plated onto 96-well tissue culture plates (Wallach, Inc., Gaithersburg, MD) in 200  $\mu$ l of EBM-2 medium without VEGF, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF) and incubated at 37°C for 72 h. Various amounts of Fab proteins were added to duplicate wells and pre-incubated at 37°C for 1 h, after which VEGF<sub>165</sub> was added to a final concentration of 16 ng/ml. After 18 h

of incubation, 0.25  $\mu$ Ci of [ $^3$ H]TdR (Amersham) was added to each well and incubated for an additional 4 h. The cells were washed once with PBS, trypsinized and harvested onto a glass filter (Printed Filtermat A, Walach) with a cell harvester (Harvester 96, MACH III, TOMTEC, Orange, CT). The membrane was washed three times with H<sub>2</sub>O and air-dried. Scintillation fluid was added and DNA incorporated radioactivity was determined on a scintillation counter (Wallach, Model 1450 Microbeta Scintillation Counter).

[0115] The ability of human anti-KDR Fab to block VEGF-stimulated mitogenic activity on HUVEC is shown in Fig. 4. All four human Fab fragments inhibited VEGF induced DNA synthesis in HUVEC in a dose-dependent manner. The Fab concentration that inhibited 50% (EC<sub>50</sub>) of VEGF-stimulated [ $^3$ H]-TdR incorporation in HUVEC, is approximately 0.5 nM for clones D2C6 and D1H4, 0.8 nM for clone D2H2, and 15 nM for clone D1F7. Controls included VEGF only (1500 cpm) and plain medium (60 cpm). Duplicate wells were assayed. The data shown are representative of at least three separate experiments.

**Example II(e). Leukemia migration assay.**

[0116] HL60 and HEL cells were washed three times with serum-free plain RPMI 1640 medium and suspended in the medium at 1 x 10<sup>6</sup>/ml. Aliquots of 100  $\mu$ l cell suspension were added to either 3- $\mu$ m-pore transwell inserts for HL60 cells, or 8- $\mu$ m-pore transwell inserts for HEL cells (Costar®, Corning Incorporated, Corning, NY) and incubated with the anti-KDR Fab proteins (5  $\mu$ g/ml) for 30 min at 37°C. The inserts were then placed into the wells of 24-well plates containing 0.5 ml of serum-free RPMI 1640 with or without VEGF165. The migration was carried out at 37°C, 5% CO<sub>2</sub> for 16-18 h for HL60 cells, or for 4 h for HEL cells. Migrated cells were collected from the lower compartments and counted with a Coulter counter (Model Z1, Coulter Electronics Ltd., Luton, England).

[0117] VEGF induced migration of HL60 and HEL cells in a dose-dependent manner with maximum stimulation achieved at 200 ng/ml (Fig. 5A). All the anti-KDR Fab fragments significantly inhibited VEGF-stimulated migration of HL60 and HEL cells (Fig. 5B). As a control, a Fab fragment of C225, an antibody directed against EGF receptor, did not show significant inhibitory effect in this assay.

**Example III. Production of IgG*****Example III(a). Construction of vectors for expression of IgG.***

[0118] Separate vectors for expression of IgG light chain and heavy chains were constructed. Cloned  $V_L$  genes were digested and ligated into the vector pKN100 (MRC). Cloned  $V_H$  genes were digested and ligated into the vector pGID105 containing the human IgG I ( $\gamma$ ) heavy chain constant domain. pKN100 and pGID105 are available from the MRC. Constructs were examined by restriction enzyme digestion and verified by dideoxynucleotide sequencing. In both cases, expression is under control of the HCMV promoter and terminated by an artificial termination sequence.

[0119] The assembled heavy and light chain genes were then cloned into Lonza GS expression vectors pEE6.1 and pEE12.1. Heavy and light chain vectors were recombined into a single vectors for stable transfection of CHO cells and NS0 cells. Transfected cells were cultured in glutamine minus medium and expressed antibodies at levels as high as 1g/L.

***Example III(b). Production and characterization of human anti-KDR IgG.***

[0120] Both IMC-2C6 and IMC-1121 were produced in stably transfected NS0 cell lines grown under serum-free conditions, and were purified from batch cell culture using Protein A affinity chromatography. The purity of the antibody preparations were analyzed by SDS-PAGE, and the concentrations were determined by ELISA, using an anti-human Fc antibody as the capturing agent and an anti-human  $\kappa$  chain antibody-horseradish peroxidase (HRP) conjugate as the detection agent. A clinical grade antibody, IMC-C225, was used as the standard for calibration. The endotoxin level of each antibody preparations was examined to ensure the products were free of endotoxin contamination.

[0121] Anti-KDR antibodies were assessed for KDR binding and blocking of VEGF binding. In the direct binding assay, various amounts of antibodies were added to KDR-coated 96-well Maxi-sorp microtiter plates (Nunc, Roskilde, Denmark) and incubated at room temperature (RT) for 1 h, after which the plates were washed 3 times with PBS containing 0.1% Tween-20. The plates were then incubated at RT for 1 h with 100  $\mu$ l of a rabbit anti-human IgG Fc-HRP conjugate (Jackson ImmunoResearch Laboratory Inc., West Grove, PA). The plates were washed and developed as above. Human antibodies IMC-2C6 and IMC-1121 were compared with IMC-1C11 (a mouse antibody specific for KDR) and IMC-C225 a chimeric antibody specific for EGFR). The anti-KDR antibodies bind to KDR in a dose-dependent manner, with IMC-1121 being the strongest binder (Fig. 6A).

[0122] The efficacy of the anti-KDR antibodies for blocking KDR from binding to VEGF was measured with a competition assay. Various amounts of antibodies were mixed with a fixed amount of KDR-AP (100 ng) and incubated at RT for 1 h. The mixtures were then transferred to 96-well microtiter plates precoated with VEGF165 (200 ng/well) and incubated at RT for an additional 2 h, after which the plates were washed 5 times and the substrate for AP (p-nitrophenyl phosphate, Sigma) was added, followed by reading the absorbance at 405nm to quantify the bound KDR-AP molecules. IC<sub>50</sub>, *i.e.*, the antibody concentration required for 50% inhibition of KDR binding to VEGF, was then calculated. The anti-KDR antibodies strongly blocked KDR from binding to VEGF (Fig. 6B), with similar potency. The IC<sub>50</sub> is approximately 0.8 to 1.0 nM for all three antibodies. The control antibody, IMC-C225 (anti-human EGFR) does not bind KDR, and does not block KDR/VEGF interaction.

[0123] Antibody affinity or avidity was determined by BIACore analysis, as above. The binding kinetics, *i.e.*, the association rate constant (*kon*) and the dissociation rate constant (*koff*), of the anti-KDR antibodies were measured and the dissociation constant, *Kd*, was calculated (Table 4).

**Table 4 - Binding kinetics of anti-KDR antibodies**

Antibody	<i>kon</i> (10 <sup>4</sup> M <sup>-1</sup> S <sup>-1</sup> )	<i>koff</i> (10 <sup>4</sup> S <sup>-1</sup> )	<i>Kd</i> (nM)
p1C11 scFv	7.7 ± 2.1*	1.0 ± 0.09	1.4 ± 0.3
IMC-1C11	13.4 ± 2.9	0.37 ± 0.13	0.27 ± 0.06
Hu-2C6 Fab	17.1 ± 5.7	5.5 ± 0.76	3.6 ± 1.7
IMC-2C6 IgG	21.2 ± 8.1	0.43 ± 0.03	0.20 ± 0.01
Hu-1121 Fab	29.6 ± 7.3	0.31 ± 0.06	0.11 ± 0.02
IMC-1121 IgG	47.9 ± 2.4	0.25 ± 0.04	0.05 ± 0.01

\* All numbers are determined by BIACore analysis and represent the mean ± SE from at least three separate determinations.

IMC-1C11 binds to immobilized KDR with a dissociation constant (*Kd*) of 0.27 nM, about 5-fold higher than its Fab counterpart. The *Kd* for IMC-2C6 is 0.2 nM, which is about 18-fold higher than that of the monovalent Hu-2C6 Fab, mainly due to an improvement in the off-rate. Affinity maturation of Hu-2C6 led to Hu-1121 Fab with a 33-fold improvement in *Kd*

(from 3.6 nM to 0.11 nM). Converting Hu-1121 Fab into bivalent IgG, IMC-1121, resulted in about 2-fold increase in overall binding avidity.

**Example III(c). *Inhibition of VEGF binding to cells and VEGF-stimulated mitogenesis of HUVEC.***

[0124] In a cell-based radioimmunoassay, various amounts of anti-KDR antibodies were mixed with a fixed amount (2 ng) of  $^{125}\text{I}$  labeled VEGF<sub>165</sub> (R & D Systems) and added to a 80-90% confluent monolayer of HUVEC grown in a 96-well microtiter plate. The plate was incubated at RT for 2 h, washed 5 times with cold PBS, and the amounts of radioactivity that bound to the endothelial cells were counted. As shown in Fig. 7A, anti-KDR antibodies competed efficiently with radiolabeled VEGF for binding to HUVEC. The data represent the means  $\pm$  SD for triplicate determinations.

[0125] The antibodies also blocked VEGF-stimulated HUVEC mitogenesis in a dose-dependent manner (Fig. 7B). As described above for Fabs, various amounts of the anti-KDR antibodies were first pre-incubated with growth factor-starved HUVEC ( $5 \times 10^3$  cells/well) at 37°C for 1 h, after which VEGF165 was added to a final concentration of 16 ng/ml. After 18 h of incubation, 0.25  $\mu\text{Ci}$  of [ $^3\text{H}$ ]-TdR (Amersham) was added to each well and incubated for an additional 4 h. The cells were washed, harvested, and DNA incorporated radioactivity was determined on a scintillation counter. IMC-1121, the antibody with the highest affinity, is the most efficacious inhibitor with an ED<sub>50</sub>, *i.e.*, the concentration that results in 50% of inhibition of [ $^3\text{H}$ ]-TdR incorporation, of about 0.7 nM, in comparison to that of 1.5 nM for both IMC-1C11 and IMC-2C6.

**Example IV. Inhibition of Leukemian Cells and Leukemia Progression**

**Example IV(a). *Expression of VEGF and KDR by leukemia cells.***

[0126] We examined VEGF and KDR expression, by RT-PCR, in three myeloid leukemia cell lines: HL60 (promyelocytic); HEL (megakaryocytic); and U937 (histiocytic). The following primers were used to amplify VEGF, Flt-1, KDR and the internal control,  $\alpha$ -actin: VEGF forward: 5'-TCGGGCCTCCGAAACCATGA-3' (SEQ ID NO:86), and reverse: 5'-CCTGGTGAGAGATCTGGTTC-3' (SEQ ID NO:87); Flt-1 forward: 5'-TTTGTGATTTGGCCTTGC-3' (SEQ ID NO:88), and reverse: 5'-CAGGCTCATGAACTTGAAAGC-3' (SEQ ID NO:89); KDR forward: 5'-GTGACCAACATGGAGTCGTG-3' (SEQ ID NO:90), and reverse: 5'-CCAGAGATTCCATGCCACTT-3' (SEQ ID NO:91);  $\alpha$ -actin forward:

5'-TCATGTTGAGACCTCAA-3' (SEQ ID NO:92), and reverse: 5'-GTCTTGCGGATGTCCACG-3' (SEQ ID NO:93). The PCR products were analyzed on a 1% agarose gel. As shown in Fig. 8A, all three lines are positive for VEGF expression, and HL60 and HEL, but not U937, are also positive for KDR expression. The three cell lines are also positive for Flt-1 expression as detected by RT-PCT (not shown).

[0127] VEGF production was examined for the three leukemia cell lines cultured under either 10% FCS or serum-free conditions. The leukemia cells were collected, washed with plain RPMI 1640 medium and seeded in 24-well plates at density of  $5 \times 10^5$ /ml, with or without the addition of 10% FCS. The cells were cultured at 37°C for 72 hr, after which total numbers of cells were counted using a Coulter counter (Model Z1, Coulter Electronics Ltd., Luton, England) and the VEGF concentration in the supernatant was determined using an ELISA kit (Biosource International, Camarillo, CA). The leukemia cells secrete significant amount of VEGF when cultured *in vitro* (Fig. 8B), and both HL60 and U937 cells produced more VEGF under serum-starving conditions.

**Example IV(b). *Inhibition of VEGF-induced leukemia cell migration.***

[0128] Leukemia cell migration assays, as described in Example II(e), were performed with the three leukemia cell lines. The migration was carried out for 16-18 h for HL60 cells, or for 4 h for HEL and U937 cells.

[0129] All three leukemia cell lines migrate in response to VEGF (Fig. 9). Incubation with anti-KDR antibodies inhibited, in a dose-dependent manner, VEGF-induced migration of HL60 and HEL cells (Fig. 9A and 9B), but had no effect on migration of U937 cells that does not express KDR (Fig. 9C). The VEGF-induced migration of U937 cells was, however, efficiently inhibited by an anti-human Flt-1 antibody, Mab 612 (Fig. 9C). As expected, the anti-EGFR antibody, IMC-C225, showed no effect on VEGF-induced migration of human leukemia cells.

**Example IV(b). *Inhibition of leukemia growth *in vivo*.***

[0130] 6 to 8-week-old sex-matched (female) NOD-SCID mice were used in all the experiments. The mice were irradiated with 3.5 Gy from a  $^{137}\text{Cs}$  gamma-ray source at a dose rate of about 0.9 Gy/min and intravenously inoculated with  $2 \times 10^7$  HL60 cells. Three days after tumor inoculation, groups of 7 to 9 mice were treated twice weekly with various doses of IMC-1C11, IMC-2C6 or IMC-1121 antibodies via intraperitoneal injection. Mice were

observed daily for signs of toxicity and recorded for time of survival. For statistical analysis, the non-parametric one-tailed Mann-Whitney Rank Sum test was used.

[0131] All untreated mice died within 17 days (Fig. 10, mean time of survival,  $14 \pm 3$  days). At this high tumor load, treatment with IMC-1C11 at 200  $\mu$ g/mouse/injection moderately increased the survival but all mice died within 35 days (mean survival:  $21 \pm 7$  days; median survival 19 days, respectively.  $p = 0.03$  compared to the control group). IMC-2C6, given at the same dose of 200  $\mu$ g/mouse/injection, significantly prolonged the mouse survival to  $34 \pm 12$  days (median = 29 days.  $p < 0.01$  compared to the control and  $p = 0.01$  compared to the IMC-1C11-treated group). The antibody with the highest affinity, IMC-1121, demonstrated a much stronger anti-leukemia effect, particularly with respect to IMC-1C11. The mice treated with IMC-1121 survived  $63 \pm 12$  days (median = 60 days.  $p < 0.001$  compared to both IMC-1C11 and IMC-2C6-treated groups). At a lower antibody dose tested (100  $\mu$ g/mouse/injection), IMC-1121 was also more efficacious. Mice treated with the lower dose of IMC-1121 survived  $46 \pm 16$  days (median = 41 days). No overt toxicities were observed in any of the antibody-treated animals throughout the course of the experiment.

[0132] Throughout this application, various publications, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, and patent applications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which the present invention pertains.

[0133] It is to be understood and expected that variations in the principles of invention herein disclosed may be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.

What is claimed is:

1. An isolated human antibody or fragment thereof which binds selectively to KDR.
2. The antibody of Claim 1, wherein the fragment is selected from the group consisting of a single chain antibody, an Fab, a single chain Fv, a diabody, and a triabody.
3. The antibody of Claim 1 or 2, wherein the antibody or fragment thereof inhibits binding of VEGF to KDR.
4. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:1 at CDRL1; SEQ ID NO:2 at CDRL2; SEQ ID NO:3 at CDRL3; SEQ ID NO:13 at CDRH1; SEQ ID NO:14 at CDRH2; and SEQ ID NO:15 at CDRH3.
5. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:26 and a heavy chain variable domain represented by SEQ ID NO:24.
6. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:81 at CDRL1; SEQ ID NO:82 at CDRL2; SEQ ID NO:83 at CDRL3; SEQ ID NO:13 at CDRH1; SEQ ID NO:14 at CDRH2; and SEQ ID NO:15 at CDRH3.
7. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:53 and a heavy chain variable domain represented by SEQ ID NO:24.
8. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises a heavy chain variable domain selected from the group consisting of SEQ ID NO:20, SEQ ID NO:24, and SEQ ID NO:31.
9. The antibody of any of Claims 1, 2, and 3, wherein the antibody comprises a light chain variable domain selected from the group consisting of SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37,

SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, and SEQ ID NO:53.

10. An isolated polynucleotide which comprises a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, and SEQ ID NO:53.

11. The polynucleotide of Claim 10 wherein the nucleotide sequence is SEQ ID NO:23.

12. The polynucleotide of Claim 10 wherein the nucleotide sequence is SEQ ID NO:25.

13. The polynucleotide of Claim 10 wherein the nucleotide sequence is SEQ ID NO:52.

14. An expression vector comprising the polynucleotide of any of Claims 10 to 13.

15. A recombinant host cell comprising the expression vector of Claim 14.

16. The recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:24 and a polypeptide comprising SEQ ID NO:26.


17. The recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:24 and a polypeptide comprising SEQ ID NO:53.


18. A method of neutralizing activation of KDR comprising administering an effective amount of an antibody of any of Claims 1 to 9.

19. A method of inhibiting angiogenesis comprising administering an effective amount of an antibody of any of Claims 1 to 9.

20. A method of reducing tumor growth comprising administering an effective amount of an antibody of any of Claims 1 to 9.

21. The method of Claim 19 or 20, wherein the antibody neutralizes KDR.
22. The method of Claim 20, wherein the tumor overexpresses KDR.
23. The method of Claim 20, wherein the tumor is a tumor of the colon.
24. The method of Claim 20, wherein the tumor is a breast tumor.
25. The method of Claim 20, wherein the tumor is a non-solid tumor.
26. The method of Claim 20, which further comprises administering of a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antagonist.
27. The method of Claim 20, which further comprises administration of a therapeutically effective amount of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.
28. The method of Claim 20, which further comprises administration of chemotherapeutic agent.
29. The method of Claim 20, which further comprises administration of radiation.

**Figure 1****BEST AVAILABLE COPY**



**Figure 2**




Figure 3





Figure 4

**Figure 5**




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

## SEQUENCE LISTING

<110> Zhu, Zhenping

<120> Human Antibodies Specific To KDR And Uses Thereof

<130> 11245/47876

<140> not assigned

<141> 2003-03-04

<150> 60/361,783

<151> 2002-03-04

<160> 93

<170> WordPerfect 8.0 for Windows

<210> 1

<211> 11

<212> PRT

<213> Human

<400> 1

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala  
5 10

<210> 2

<211> 7

<212> PRT

<213> Human

<400> 2

Asp Ser Ser Asn Arg Ala Thr  
5

<210> 3

<211> 9

<212> PRT

<213> Human

<400> 3

Leu Gln His Asn Thr Phe Pro Pro Thr  
5

<210> 4

<211> 11

<212> PRT

<213> Human

<400> 4

Arg Ala Ser Gln Gly Ile Ser Ser Arg Leu Ala  
5 10

<210> 5

<211> 7

<212> PRT

<213> Human

<400> 5

Ala Ala Ser Ser Leu Gln Thr  
5

<210> 6

<211> 9

<212> PRT

<213> Human

<400> 6

Gln Gln Ala Asn Arg Phe Pro Pro Thr  
5

<210> 7

<211> 14

<212> PRT

<213> Human

<400> 7

Ala Gly Thr Thr Thr Asp Leu Thr Tyr Tyr Asp Leu Val Ser  
5 10

<210> 8

<211> 7

<212> PRT

<213> Human

<400> 8

Asp Gly Asn Lys Arg Pro Ser  
5

<210> 9

<211> 10

<212> PRT

<213> Human

<400> 9

Asn Ser Tyr Val Ser Ser Arg Phe Tyr Val  
5 10

<210> 10

<211> 13

<212> PRT

<213> Human

<400> 10

Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn Thr Ala Asn  
5 10

<210> 11

<211> 7

<212> PRT

&lt;213&gt; Human

&lt;400&gt; 11

Asn Asn Asn Gln Arg Pro Ser  
5

&lt;210&gt; 12

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 12

Ala Ala Trp Asp Asp Ser Leu Asn Gly His Trp Val  
5 10

&lt;210&gt; 13

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 13

Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn  
5 10

&lt;210&gt; 14

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 14

Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys  
5 10 15

Gly

17

&lt;210&gt; 15

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 15

Val Thr Asp Ala Phe Asp Ile  
5

&lt;210&gt; 16

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 16

Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser  
5 10

<210> 17  
 <211> 18  
 <212> PRT  
 <213> Human

<400> 17

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
 5 10 15

Gln Gly  
 18

<210> 18  
 <211> 16  
 <212> PRT  
 <213> Human

<400> 18

Gly Tyr Asp Tyr Tyr Asp Ser Ser Gly Val Ala Ser Pro Phe Asp Tyr  
 5 10 15

<210> 19  
 <211> 375  
 <212> DNA  
 <213> Human

<400> 19

gag gtc cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc 48  
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 5 10 15

tca gtg aag gtc tcc tgc aag gct tct gga ggc acc ttc agc agc tat 96  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr  
 20 25 30

gct atc agc tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Ile Glu Trp Met  
 35 40 45

gga ggg atc atc cct atc ttt ggt aca gca aac tac gca cag aag ttc 192  
 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
 50 55 60

cag ggc aga gtc act ttt acc gcg gac aaa tcc acg agt aca gcc tat 240  
 Gln Gly Arg Val Thr Phe Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
 65 70 75 80

atg gag ttg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt 288  
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gga tac gat tac tat gat agt agt ggc gtg gct tcc ccc ttt 336  
 Ala Arg Gly Tyr Asp Tyr Tyr Asp Ser Ser Gly Val Ala Ser Pro Phe  
 100 105 110

gac tac tgg ggc cag gga acc ctg gtc acc gtc tca agc 375  
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120 125

<210> 20  
 <211> 125  
 <212> PRT  
 <213> Human

<400> 20

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
 50 55 60  
 Gln Gly Arg Val Thr Phe Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Gly Tyr Asp Tyr Tyr Asp Ser Ser Gly Val Ala Ser Pro Phe  
 100 105 110  
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120 125

<210> 21  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 21

cag tct gtg ctg act cag cca ccc tca gcg tct ggg acc ccc ggg cag 48  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
 5 10 15  
 agg gtc acc atc tct tgt tct gga agc acc tcc aac atc ggt act aat 96  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn  
 20 25 30  
 act gca aac tgg ttc cag cag ctc cca gga acg gcc ccc aaa ctc ctc 144  
 Thr Ala Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Ile  
 35 40 45  
 atc cac aat aat aat cag cgg ccc tca ggg gtc cct gac cga ttc tct 192  
 Ile His Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 ggc tcc aag tct ggc acc tca gcc tcc ctg gcc atc agt ggg ctc cag 240  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
 65 70 75 80  
 tct gag gat gag gct gat tat tac tgt gca gca tgg gat gac agc ctg 288  
 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
 85 90 95  
 aat ggc cat tgg gtg ttc ggc gga ggg acc aag ctg acc gtc ctg 333

Asn	Gly	His	Trp	Val	Phe	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu
100						105					110		

<210> 22  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 22

Gln	Ser	Val	Leu	Thr	Gln	Pro	Pro	Ser	Ala	Ser	Gly	Thr	Pro	Gly	Gln
					5				10			15			

Arg	Val	Thr	Ile	Ser	Cys	Ser	Gly	Ser	Thr	Ser	Asn	Ile	Gly	Thr	Asn
						20			25			30			

Thr	Ala	Asn	Trp	Phe	Gln	Gln	Leu	Pro	Gly	Thr	Ala	Pro	Lys	Leu	Leu
					35			40		45					

Ile	His	Asn	Asn	Asn	Gln	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser
					50			55		60					

Gly	Ser	Lys	Ser	Gly	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Ser	Gly	Leu	Gln
					65			70		75		80			

Ser	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Ala	Trp	Asp	Asp	Ser	Leu
					85			90		95					

Asn	Gly	His	Trp	Val	Phe	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	
					100			105		110				

<210> 23  
 <211> 348  
 <212> DNA  
 <213> Human

<400> 23

gag	gtg	cag	ctg	gtg	cag	tct	ggg	gga	ggc	ctg	gtc	aag	cct	ggg	ggg
Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly
						5			10			15			

tcc	ctg	aga	ctc	tcc	tgt	gca	gcc	tct	gga	ttc	acc	ttc	agt	agc	tat
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
						20			25			30			

agc	atg	aac	tgg	gtc	cgc	cag	gct	cca	ggg	aag	ggg	ctg	gag	tgg	gtc
Ser	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
						35			40		45				

tca	tcc	att	agt	agt	agt	agt	tac	ata	tac	tac	gca	gac	tca	gtg	
Ser	Ser	Ile	Ser	Ser	Ser	Ser	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	
							50		55		60				

aag	ggc	cga	ttc	acc	atc	tcc	aga	gac	aac	gcc	aag	aac	tca	ctg	tat
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr
						65			70		75		80		

ctg	caa	atg	aac	agc	ctg	aga	gcc	gag	gac	acg	gct	gtg	tat	tac	tgt
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
						85			90		95				

gcg aga gtc aca gat gct ttt gat atc tgg ggc caa ggg aca atg gtc 336  
 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

acc gtc tca agc 348  
 Thr Val Ser Ser  
 115

<210> 24  
 <211> 116  
 <212> PRT  
 <213> Human

<400> 24

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

Thr Val Ser Ser  
 115

<210> 25  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 25

gaa att gtg atg aca cag tct cca gcc acc ctg tct ttg tct cca ggg 48  
 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
 5 10 15

gaa aga gcc acc ctc tcc tgc agg gcc agt cag agt gtt agc agc tac 96  
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
 20 25 30

tta gcc tgg tac caa cag aaa cct ggc cag gct ccc agg ctc ctc atc 144  
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45

tat gat tca tcc aac agg gcc act ggc atc cca gcc aga ttc agt ggc 192  
 Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

agt ggg tct ggg aca gac ttc act ctc acc atc agc agc cta gag cct 240

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
 65 70 75 80  
 gaa gat ttt gca act tat tac tgt cta cag cat aac act ttt cct ccg 288  
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Phe Pro Pro  
 85 90 95  
 acg ttc ggc caa ggg acc aag gtg gaa atc aaa 321  
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 26  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 26

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45

Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Phe Pro Pro  
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 27  
 <211> 348  
 <212> DNA  
 <213> Human

<400> 27

gag gtc cag ctg gtg cag tct ggg gga ggc ctg gtc aag cct ggg ggg 48  
 Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt agc tat 96  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

agc atg aac tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg gtc 144  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

tca tcc att agt agt agt agt tac ata tac tac gca gac tca gtg 192  
 Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

aag ggc cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat 240

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
65					70					75				80		
ctg	caa	atg	aac	agc	ctg	aga	gcc	gag	gac	acg	gct	gtg	tat	tac	tgt	288
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85				90				95			
gcg	aga	gtc	aca	gat	gct	ttt	gat	atc	tgg	ggc	caa	ggg	aca	atg	gtc	336
Ala	Arg	Val	Thr	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	Val	
					100			105				110				
acc	gtc	tca	agc													348
Thr	Val	Ser	Ser													
					115											
<210> 28																
<211> 330																
<212> DNA																
<213> Human																
<400> 28																
cag	tct	gcc	ctg	act	cag	cct	gcc	tcc	ctg	tct	ggg	tct	cct	gga	cag	48
Gln	Ser	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Leu	Ser	Gly	Ser	Pro	Gly	Gln	
					5				10				15			
tcg	atc	acc	atc	tcc	tgc	gct	gga	acc	acc	act	gat	ctt	aca	tat	tat	96
Ser	Ile	Thr	Ile	Ser	Cys	Ala	Gly	Thr	Thr	Thr	Asp	Leu	Thr	Tyr	Tyr	
					20			25				30				
gac	ctt	gtc	tcc	tgg	tac	caa	cag	cac	cca	ggc	caa	gca	ccc	aaa	ctc	144
Asp	Leu	Val	Ser	Trp	Tyr	Gln	Gln	His	Pro	Gly	Gln	Ala	Pro	Lys	Leu	
					35			40				45				
gtg	att	tat	gac	ggc	aat	aag	cgg	ccc	tca	gga	gtt	tct	aat	cgc	ttc	192
Val	Ile	Tyr	Asp	Gly	Asn	Lys	Arg	Pro	Ser	Gly	Val	Ser	Asn	Arg	Phe	
					50			55				60				
tct	ggc	tcc	aag	tct	ggc	aac	acg	gcc	tcc	ctg	aca	atc	tct	gga	ctc	240
Ser	Gly	Ser	Lys	Ser	Gly	Asn	Thr	Ala	Ser	Ile	Thr	Ile	Ser	Gly	Leu	
					65			70			75		80			
cag	gct	gag	gag	gct	gat	tat	tac	tgc	aac	tca	tat	gta	agc	agc		288
Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Asn	Ser	Tyr	Val	Ser	Ser	
					85			90				95				
agg	ttt	tat	gtc	tcc	gga	act	ggg	acc	aag	gtc	acc	gtc	cta			330
Arg	Phe	Tyr	Val	Phe	Gly	Thr	Gly	Thr	Lys	Val	Thr	Val	Leu			
					100			105				110				
<210> 29																
<211> 110																
<212> PRT																
<213> Human																
<400> 29																
Gln	Ser	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Leu	Ser	Gly	Ser	Pro	Gly	Gln	
					5				10				15			
Ser	Ile	Thr	Ile	Ser	Cys	Ala	Gly	Thr	Thr	Thr	Asp	Leu	Thr	Tyr	Tyr	
					20			25				30				

Asp Leu Val Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu  
 35 40 45

Val Ile Tyr Asp Gly Asn Lys Arg Pro Ser Gly Val Ser Asn Arg Phe  
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu  
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Val Ser Ser  
 85 90 95

Arg Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu  
 100 105 110

&lt;210&gt; 30

&lt;211&gt; 348

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 30

gaa gtg cag ctg gtg cag tct ggg gga ggc ctg gtc aag cct ggg ggg 48  
 Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt agc tat 96  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

agc atg aac tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg gtc 144  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

tca tcc att agt agt agt agt tac ata tac tac gca gac tca gtg 192  
 Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

aag ggc cga ttc acc atc tcc aga gac aac gcc aag gac tca ctg tat 240  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Ser Leu Tyr  
 65 70 75 80

ctg caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt 288  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gtc aca gat gct ttt gat atc tgg ggc caa ggg aca atg gtc 336  
 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

acc gtc tca agc 348  
 Thr Val Ser Ser  
 115

&lt;210&gt; 31

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 31

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ser Ile Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110  
 Thr Val Ser Ser  
 115

<210> 32  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 32

gac atc cag ttg acc cag tct cca tct tct gtg tct gca tct gta gga	48
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
gac aga gtc acc atc act tgt cgg gcg agt cag ggt att agt agt cgg	96
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg	
20 25 30	
tta gcc tgg tat cag cag aaa cca ggg aaa gcc cct aag ctc ctg atc	144
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile	
35 40 45	
tat gct gca tcc agt ttg caa act ggg gtc cca tca agg ttc agc ggc	192
Tyr Ala Ala Ser Ser Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
agt gga tct ggg aca gat ttc act ctc act atc agc agc ctg cag cct	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro	
65 70 75 80	
gaa gat ttt gca act tac tat tgt caa cag gct aac agg ttc cct ccg	288
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Arg Phe Pro Pro	
85 90 95	
act ttc ggc cct ggg acc aaa gtg gat atc aaa	321
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 33  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 33

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg  
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
 35 40 45

Tyr Ala Ala Ser Ser Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Arg Phe Pro Pro  
 85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys  
 100 105

<210> 34  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 34

cag tct gtc gtg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag 48  
 Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 5 10 15

agg gtc acc atc tcc tgc act ggg agc cac tcc aac ttc ggg gca gga 96  
 Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly  
 20 25 30

act gat gta cat tgg tac caa cac ctt cca gga aca gcc ccc aga ctc 144  
 Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu  
 35 40 45

ctc att cat gga gac agt aat cgg ccc tcc ggg gtc cct gac cga ttc 192  
 Leu Ile His Gly Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
 50 55 60

tct ggc tcc agg tct ggc acc tca gcc tcc ctg gcc atc act ggg ctc 240  
 Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu  
 65 70 75 80

cgg gtt gag gat gag gct gat tat tac tgt cag tcg tat gac tat ggc 288  
 Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly  
 85 90 95

ctg aga ggt tgg gtg ttc ggc ggg acc aag ctg acc gtc ctt 333  
 Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
 100 105 110

<210> 35  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 35

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly  
 20 25 30

Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu  
 35 40 45

Leu Ile His Gly Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
 50 55 60

Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu  
 65 70 75 80

Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly  
 85 90 95

Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
 100 105 110

<210> 36  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 36

gat gtt gtg atg act cag tct cca tcg tcc ctg tct gca tct gta ggg 48  
 Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
 5 10 15

gac aga gtc acc atc act tgc cgg gca agt cag aac att aac aac tat 96  
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Asn Tyr  
 20 25 30

tta aat tgg tat caa cag aaa cca gga aaa gcc cct aag ctc ctg atc 144  
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
 35 40 45

tat gct gcc tcc act ttg caa agt ggg gtc cca tca agg ttc agt ggc 192  
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

agt gga tct ggg aca gat ttc act ctc acc atc acc agc cta cag cct 240  
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro  
 65 70 75 80

gaa gat tct gca act tat tac tgc caa cag tat tcc cgt tat cct ccc 288  
 Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Arg Tyr Pro Pro  
 85 90 95

act ttc ggc gga ggg acc aag gtg gag atc aca 321  
 Thr Phe Gly Gly Thr Lys Val Glu Ile Thr  
 100 105

<210> 37  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 37

Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
                   5                         10                         15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Asn Tyr  
                   20                         25                         30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
                   35                         40                         45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
                   50                         55                         60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro  
                   65                         70                         75                         80

Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Arg Tyr Pro Pro  
                   85                         90                         95

Thr Phe Gly Gly Thr Lys Val Glu Ile Thr  
                   100                         105

<210> 38  
 <211> 330  
 <212> DNA  
 <213> Human

<400> 38

cag tct gcc ctg act cag cct gcc tcc gtg tct ggg tct cgt gga cag   48  
 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Arg Gly Gln  
                   5                         10                         15

tcg atc acc ctc tcc tgc acc ggc tcc agc act gat gtg ggt aat tat   96  
 Ser Ile Thr Leu Ser Cys Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr  
                   20                         25                         30

aac tat atc tcc tgg tac caa caa cac cca ggc caa gcc ccc aaa ctc   144  
 Asn Tyr Ile Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu  
                   35                         40                         45

ttg att tac gat gtc act agt cgg ccc tca ggt gtt tct gat cgc ttc   192  
 Leu Ile Tyr Asp Val Thr Ser Arg Pro Ser Gly Val Ser Asp Arg Phe  
                   50                         55                         60

tct ggc tcc aag tca ggc ctc acg gcc tcc ctg acc atc tct gga ctc   240  
 Ser Gly Ser Lys Ser Gly Leu Thr Ala Ser Leu Thr Ile Ser Gly Leu  
                   65                         70                         75                         80

cag cct gaa gac gag gct gac tat tac tgc aac tcc tat tct gcc acc   288  
 Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ser Ala Thr  
                   85                         90                         95

gac act ctt gtt ttt ggc gga ggg acc aag ctg acc gtc cta   330  
 Asp Thr Leu Val Phe Gly Gly Thr Lys Leu Thr Val Leu

<210> 39  
 <211> 110  
 <212> PRT  
 <213> Human

<400> 39

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Arg Gly Gln  
                   5                  10                  15  
  
 Ser Ile Thr Leu Ser Cys Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr  
                   20                  25                  30  
  
 Asn Tyr Ile Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu  
                   35                  40                  45  
  
 Leu Ile Tyr Asp Val Thr Ser Arg Pro Ser Gly Val Ser Asp Arg Phe  
                   50                  55                  60  
  
 Ser Gly Ser Lys Ser Gly Leu Thr Ala Ser Leu Thr Ile Ser Gly Leu  
                   65                  70                  75                  80  
  
 Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ser Ala Thr  
                   85                  90                  95  
  
 Asp Thr Leu Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
                   100                  105                  110

<210> 40  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 40

cag gct gtg ctg act cag ccg tcc tca gtg tct ggg gcc cca gga cag   48  
 Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ala Pro Gly Gln  
                   5                  10                  15  
  
 agg gtc acc atc tcc tgc act ggg caa agc tcc aat atc ggg gca gat   96  
 Arg Val Thr Ile Ser Cys Thr Gly Gln Ser Ser Asn Ile Gly Ala Asp  
                   20                  25                  30  
  
 tat gat gta cat tgg tac cag caa ttt cca gga aca gcc ccc aaa ctc   144  
 Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu  
                   35                  40                  45  
  
 ctc atc tat ggt cac aac aat cgg ccc tca ggg gtc cct gac cga ttc   192  
 Leu Ile Tyr Gly His Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
                   50                  55                  60  
  
 tct ggc tcc aag tct ggc acc tca gtc tcc ctg gtc atc agt ggg ctc   240  
 Ser Gly Ser Lys Ser Gly Thr Ser Val Ser Leu Val Ile Ser Gly Leu  
                   65                  70                  75                  80  
  
 cag gct gag gat gag gct gat tat tat tgc cag tcc tat gac agc agt   288  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser  
                   85                  90                  95  
  
 cta agt ggt ttg gta ttc ggc gga ggg acc aag gtg acc gtc cta   333  
 Leu Ser Gly Leu Val Phe Gly Gly Thr Lys Val Thr Val Leu  
                   100                  105                  110

<210> 41  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 41

Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                  15  
  
 Arg Val Thr Ile Ser Cys Thr Gly Gln Ser Ser Asn Ile Gly Ala Asp  
                   20                         25                  30  
  
 Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu  
                   35                         40                  45  
  
 Leu Ile Tyr Gly His Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
                   50                         55                  60  
  
 Ser Gly Ser Lys Ser Gly Thr Ser Val Ser Leu Val Ile Ser Gly Leu  
                   65                         70                  75                  80  
  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser  
                   85                         90                  95  
  
 Leu Ser Gly Leu Val Phe Gly Gly Thr Lys Val Thr Val Leu  
                   100                         105                 110

<210> 42  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 42

gac atc cag ttg acc cag tct cca tct tct gtg tct gca tct gtt gga.   48  
 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
                   5                         10                  15  
  
 gac agc gtc acc atc act tgt cgg gcg agt cag gat att agc agc tgg   96  
 Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Trp  
                   20                         25                  30  
  
 tta gcc tgg tat caa cag aaa cca ggg gag gcc cct aag ctc ctg atc   144  
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile  
                   35                         40                  45  
  
 tat gct gca tcc ctt ctt caa agt ggg gtc cca tca cgg ttc agc ggc   192  
 Tyr Ala Ala Ser Leu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
                   50                         55                  60  
  
 agt gga tct ggg aca gat ttc gct ctc act atc aac agc ctg cag cct   240  
 Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Asn Ser Leu Gln Pro  
                   65                         70                  75                  80  
  
 gaa gat ttt gca act tac ttt tgt caa cag gct gac agt ttc cct ccc   288  
 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Asp Ser Phe Pro Pro  
                   85                         90                  95  
  
 acc ttc ggc caa ggg aca cgg ctg gag att aaa  
 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
                   100                         105

<210> 43  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 43

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
 5 10 15

Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Trp  
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile  
 35 40 45

Tyr Ala Ala Ser Leu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Asn Ser Leu Gln Pro  
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Asp Ser Phe Pro Pro  
 85 90 95

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
 100 105

<210> 44  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 44

gac atc gag ttg acc cag tct cca tct tcc gtg tct gca tct gtg gga 48  
 Asp Ile Glu Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
 5 10 15

gac aga gtc acc ctc act tgt cgg gcg agt cag agt att aag agg tgg 96  
 Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Lys Arg Trp  
 20 25 30

tta gcc tgg tat cag cag aaa cca ggg aag gcc cct agg ctc ctc atc 144  
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile  
 35 40 45

tat gct gca tcc act ttg caa agt ggg gtc cca tca agg ttc agc ggc 192  
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

ggt gga tct ggg aca gat ttc act ctc acc atc aac agc ctg cag cct 240  
 Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro  
 65 70 75 80

gaa gat ttt gca att tac tac tgt caa cag gct aac agt ttc cct ccc 288  
 Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Pro  
 85 90 95

act ttc ggc cct ggg acc aaa gtg gat atc aaa  
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys  
 100 105

<210> 45  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 45

Asp	Ile	Glu	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Val	Ser	Ala	Ser	Val	Gly
					5					10				15	
Asp	Arg	Val	Thr	Leu	Thr	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Lys	Arg	Trp
					20					25				30	
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Arg	Leu	Leu	Ile
					35					40				45	
Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
					50					55			60		
Gly	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro
					65					75				80	
Glu	Asp	Phe	Ala	Ile	Tyr	Tyr	Cys	Gln	Gln	Ala	Asn	Ser	Phe	Pro	Pro
					85					90				95	
Thr	Phe	Gly	Pro	Gly	Thr	Lys	Val	Asp	Ile	Lys					
					100					105					

<210> 46  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 46

cag	tct	gtc	gtg	acg	cag	ccg	ccc	tca	gtg	tct	ggg	gcc	cca	ggg	cag	48
Gln	Ser	Val	Val	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ala	Pro	Gly	Gln	
															15	
5									10							
agg	gtc	acc	atc	tcc	tgc	agt	ggg	agc	agg	tcc	aac	atc	ggg	gca	cac	96
Arg	Val	Thr	Ile	Ser	Cys	Ser	Gly	Ser	Arg	Ser	Asn	Ile	Gly	Ala	His	
															30	
20									25							
tat	gaa	gtc	cag	tgg	tac	cag	cag	ttt	ccg	gga	gca	gcc	ccc	aaa	ctc	144
Tyr	Glu	Val	Gln	Trp	Tyr	Gln	Gln	Phe	Pro	Gly	Ala	Ala	Pro	Lys	Leu	
															45	
35									40							
ctc	atc	tat	ggt	gac	acc	aat	cgg	ccc	tca	ggg	gtc	cct	gac	cga	ttc	192
Leu	Ile	Tyr	Gly	Asp	Thr	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	
															50	
50									55						60	
tct	gcc	tcc	cac	tct	ggc	acc	tca	gcc	tcc	ctt	gcc	atc	aca	ggg	ctc	240
Ser	Ala	Ser	His	Ser	Gly	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Leu	
															65	
65									70						75	
cag	gct	gag	gat	gag	gct	gat	tat	tac	tgc	cag	tcg	tat	gac	acc	agt	288
Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Thr	Ser	
															85	
85									90						95	
cta	cgt	ggt	ccg	gtg	ttc	ggc	gga	ggg	acc	aag	ctg	acc	gtc	cta	333	
Leu	Arg	Gly	Pro	Val	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu		
															100	
										105				110		

<210> 47  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 47

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                         15  
  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ala His  
                   20                         25                         30  
  
 Tyr Glu Val Gln Trp Tyr Gln Gln Phe Pro Gly Ala Ala Pro Lys Leu  
                   35                         40                         45  
  
 Leu Ile Tyr Gly Asp Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
                   50                         55                         60  
  
 Ser Ala Ser His Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu  
                   65                         70                         75                         80  
  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser  
                   85                         90                         95  
  
 Leu Arg Gly Pro Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
                   100                         105                         110

<210> 48  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 48

cag tct gtc gtg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag   48  
 Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                         15  
  
 agg gtc acc atc tcc tgc act ggg agc agc tcc aac atc ggg aca ggt   96  
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Thr Gly  
                   20                         25                         30  
  
 tat gat gta cat tgg tac cag cag gtt cca gga tca gcc ccc aaa ctc   144  
 Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Lys Leu  
                   35                         40                         45  
  
 ctc atc tat gct tac acc aat cgg ccc tca ggg gtc cct gac cga ttc   192  
 Leu Ile Tyr Ala Tyr Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
                   50                         55                         60  
  
 tct ggc tcc aag tct ggc atg tca gcc tcc ctg gtc atc ggt ggt ctc   240  
 Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Val Ile Gly Gly Leu  
                   65                         70                         75                         80  
  
 cag gct gag gat gag gct gat tat tac tgc cag tcc ttt gac gac agc   288  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Asp Ser  
                   85                         90                         95  
  
 ctg aat ggt ctt gtc ttc gga cct ggg acc tcg gtc acc gtc ctc   333  
 Leu Asn Gly Leu Val Phe Gly Pro Gly Thr Ser Val Thr Val Leu  
                   100                         105                         110

<210> 49  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 49

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                         15  
  
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Asn Ile Gly Thr Gly  
                   20                         25                         30  
  
 Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Lys Leu  
                   35                         40                         45  
  
 Leu Ile Tyr Ala Tyr Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
                   50                         55                         60  
  
 Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Val Ile Gly Gly Leu  
                   65                         70                         75                         80  
  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Asp Ser  
                   85                         90                         95  
  
 Leu Asn Gly Leu Val Phe Gly Pro Gly Thr Ser Val Thr Val Leu  
                   100                         105                         110

<210> 50  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 50

cag tct gtg ttg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag       48  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                         15  
  
 agg gtc acc atc tcc tgc act ggg agc cac tcc aac ttc ggg gca ggt       96  
 Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly  
                   20                         25                         30  
  
 act gat gtc cat tgg tac caa cac ctt cca gga aca gcc ccc aga ctc      144  
 Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu  
                   35                         40                         45  
  
 ctc att cat gga gac act cat cgg ccc tcc ggg gtc gct gac cga ttc      192  
 Leu Ile His Gly Asp Thr His Arg Pro Ser Gly Val Ala Asp Arg Phe  
                   50                         55                         60  
  
 tct ggc tcc agg tct ggc gcc tca gcc tcc ctg gcc atc act ggg ctc      240  
 Ser Gly Ser Arg Ser Gly Ala Ser Ala Ser Leu Ala Ile Thr Gly Leu  
                   65                         70                         75                         80  
  
 cg gtt gag gat gag gct gat tat tac tgt cag tcg tat gac tat ggc      288  
 Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly  
                   85                         90                         95  
  
 ctg aga ggt tgg gtg ttc ggc ggg acc aag ctg acc gtc ctt      333  
 Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
                   100                         105                         110

<210> 51  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 51

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
                   5                         10                         15  
  
 Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly  
                   20                         25                         30  
  
 Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu  
                   35                         40                         45  
  
 Leu Ile His Gly Asp Thr His Arg Pro Ser Gly Val Ala Asp Arg Phe  
                   50                         55                         60  
  
 Ser Gly Ser Arg Ser Gly Ala Ser Ala Ser Leu Ala Ile Thr Gly Leu  
                   65                         70                         75                         80  
  
 Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly  
                   85                         90                         95  
  
 Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
                   100                         105                         110

<210> 52  
 <211> 321  
 <212> DNA  
 <213> Human

<400> 52

gac atc cag atg acc cag tct cca tct tcc gtg tct gca tct ata gga           48  
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Ile Gly  
                   5                         10                         15  
  
 gac aga gtc acc atc act tgt cgg gcg agt cag ggt att gac aac tgg           96  
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Asn Trp  
                   20                         25                         30  
  
 tta ggc tgg tat cag cag aaa cct ggg aaa gcc cct aaa ctc ctg atc           144  
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
                   35                         40                         45  
  
 tac gat gca tcc aat ttg gac aca ggg gtc cca tca agg ttc agt gga           192  
 Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly  
                   50                         55                         60  
  
 agt gga tct ggg aca tat ttt act ctc acc atc agt agc ctg caa gct           240  
 Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala  
                   65                         70                         75                         80  
  
 gaa gat ttt gca gtt tat ttc tgt caa cag gct aaa gct ttt cct ccc           288  
 Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ala Lys Ala Phe Pro Pro  
                   85                         90                         95  
  
 act ttc ggc gga ggg acc aag gtg gac atc aaa  
 Thr Phe Gly Gly Thr Lys Val Asp Ile Lys  
                   100                         105

<210> 53  
 <211> 107  
 <212> PRT  
 <213> Human

<400> 53

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Ile Gly  
5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Asn Trp  
20 25 30

Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala  
65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ala Lys Ala Phe Pro Pro  
85 90 95

Thr Phe Gly Gly Thr Lys Val Asp Ile Lys  
100 105

<210> 54  
<211> 13  
<212> PRT  
<213> Human

<400> 54

Thr Gly Ser His Ser Asn Phe Gly Ala Gly Thr Asp Val  
5 10

<210> 55  
<211> 7  
<212> PRT  
<213> Human

<400> 55

Gly Asp Ser Asn Arg Pro Ser  
5

<210> 56  
<211> 11  
<212> PRT  
<213> Human

<400> 56

Gln Ser Tyr Asp Tyr Gly Leu Arg Gly Trp Val  
5 10

<210> 57  
<211> 11  
<212> PRT  
<213> Human

<400> 57

Arg Ala Ser Gln Asn Ile Asn Asn Tyr Leu Asn  
5 10

<210> 58  
<211> 7  
<212> PRT  
<213> Human

<400> 58

Ala Ala Ser Thr Leu Gln Ser  
5

<210> 59  
<211> 9  
<212> PRT  
<213> Human

<400> 59

Gln Gln Tyr Ser Arg Tyr Pro Pro Thr  
5

<210> 60  
<211> 14  
<212> PRT  
<213> Human

<400> 60

Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr Asn Tyr Ile Ser  
5 10

<210> 61  
<211> 7  
<212> PRT  
<213> Human

<400> 61

Asp Val Thr Ser Arg Pro Ser  
5

<210> 62  
<211> 10  
<212> PRT  
<213> Human

<400> 62

Asn Ser Tyr Ser Ala Thr Asp Thr Leu Val  
5 10

<210> 63  
<211> 14  
<212> PRT  
<213> Human

<400> 63

Thr Gly Gln Ser Ser Asn Ile Gly Ala Asp Tyr Asp Val His  
5 10

<210> 64  
<211> 7  
<212> PRT  
<213> Human

<400> 64

Gly His Asn Asn Arg Pro Ser  
5

<210> 65  
<211> 11  
<212> PRT  
<213> Human

<400> 65

Gln Ser Tyr Asp Ser Ser Leu Ser Gly Leu Val  
5 10

<210> 66  
<211> 11  
<212> PRT  
<213> Human

<400> 66

Arg Ala Ser Gln Asp Ile Ser Ser Trp Leu Ala  
5 10

<210> 67  
<211> 7  
<212> PRT  
<213> Human

<400> 67

Ala Ala Ser Leu Leu Gln Ser  
5

<210> 68  
<211> 9  
<212> PRT  
<213> Human

<400> 68

Gln Gln Ala Asp Ser Phe Pro Pro Thr  
5

<210> 69  
<211> 11  
<212> PRT  
<213> Human

<400> 69

Arg Ala Ser Gln Ser Ile Lys Arg Trp Leu Ala  
5 10

<210> 70  
<211> 7  
<212> PRT  
<213> Human

<400> 70

Ala Ala Ser Thr Leu Gln Ser  
5

<210> 71  
<211> 9  
<212> PRT  
<213> Human

<400> 71

Gln Gln Ala Asn Ser Phe Pro Pro Thr  
5

<210> 72  
<211> 14  
<212> PRT  
<213> Human

<400> 72

Ser Gly Ser Arg Ser Asn Ile Gly Ala His Tyr Glu Val Gln  
5 10

<210> 73  
<211> 7  
<212> PRT  
<213> Human

<400> 73

Gly Asp Thr Asn Arg Pro Ser  
5

<210> 74  
<211> 11  
<212> PRT  
<213> Human

<400> 74

Gln Ser Tyr Asp Thr Ser Leu Arg Gly Pro Val  
5 10

<210> 75  
<211> 14  
<212> PRT  
<213> Human

<400> 75

Thr Gly Ser Ser Ser Asn Ile Gly Thr Gly Tyr Asp Val His  
5 10

<210> 76  
<211> 7  
<212> PRT  
<213> Human

<400> 76

Ala Tyr Thr Asn Arg Pro Ser  
5

<210> 77  
<211> 11  
<212> PRT  
<213> Human

<400> 77

Gln Ser Phe Asp Asp Ser Leu Asn Gly Leu Val  
5 10

<210> 78  
<211> 14  
<212> PRT  
<213> Human

<400> 78

Thr Gly Ser His Ser Asn Phe Gly Ala Gly Thr Asp Val His  
5 10

<210> 79  
<211> 7  
<212> PRT  
<213> Human

<400> 79

Gly Asp Thr His Arg Pro Ser  
5

<210> 80  
<211> 11  
<212> PRT  
<213> Human

<400> 80

Gln Ser Tyr Asp Tyr Gly Leu Arg Gly Trp Val  
5 10

<210> 81  
<211> 11  
<212> PRT  
<213> Human

<400> 81

Arg Ala Ser Gln Gly Ile Asp Asn Trp Leu Gly  
5 10

<210> 82  
 <211> 7  
 <212> PRT  
 <213> Human

<400> 82

Asp Ala Ser Asn Leu Asp Thr  
 5

<210> 83  
 <211> 9  
 <212> PRT  
 <213> Human

<400> 83

Gln Gln Ala Lys Ala Phe Pro Pro Thr  
 5

<210> 84  
 <211> 2351  
 <212> DNA  
 <213> Human

<400> 84

ggtaccgag aaagaaccgg ctcccgagtt ctgggcattt cgcccggtc gaggtgcagg 59

atg cag agc aag gtg ctg ctg gcc gtc ctg tgg ctc tgc gtg gag 107  
 Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu  
 5 10 15

acc cgg gcc gcc tct gtg ggt ttg cct agt gtt tct ctt gat ctg ccc 155  
 Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro  
 20 25 30

agg ctc agc ata caa aaa gac ata ctt aca att aag gct aat aca act 203  
 Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr  
 35 40 45

ctt caa att act tgc agg gga cag agg gac ttg gac tgg ctt tgg ccc 251  
 Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro  
 50 55 60

aat aat cag agt ggc agt gag caa agg gtg gag gtg act gag tgc agc 299  
 Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser  
 65 70 75 80

gat ggc ctc ttc tgt aag aca ctc aca att cca aaa gtg atc gga aat 347  
 Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn  
 85 90 95

gac act gga gcc tac aag tgc ttc tac cgg gaa act gac ttg gcc tcg 395  
 Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser  
 100 105 110

gtc att tat gtc tat gtt caa gat tac aga tct cca ttt att gct tct 443  
 Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser  
 115 120 125

gtt agt gac caa cat gga gtc gtg tac att act gag aac aaa aac aaa 491  
 Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys

130	135	140	
act gtg gtg att cca tgt ctc ggg tcc att tca aat ctc aac gtg tca Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser	145 150	155	539 160
ctt tgt gca aga tac cca gaa aag aga ttt gtt cct gat ggt aac aga Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg	165	170	587 175
att tcc tgg gac agc aag aag ggc ttt act att ccc agc tac atg atc Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile	180	185	635 190
agc tat gct ggc atg gtc ttc tgt gaa gca aaa att aat gat gaa agt Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser	195	200	683 205
tac cag tct att atg tac ata gtt gtc gtt gta ggg tat agg att tat Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr	210	215	731 220
gat gtg gtt ctg agt ccg tct cat gga att gaa cta tct gtt gga gaa Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu	225	230	779 240
aag ctt gtc tta aat tgt aca gca aga act gaa cta aat gtg ggg att Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile	245	250	827 255
gac ttc aac tgg gaa tac cct tct tcg aag cat cag cat aag aaa ctt Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu	260	265	875 270
gta aac cga gac cta aaa acc cag tct ggg agt gag atg aag aaa ttt Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe	275	280	923 285
ttg agc acc tta act ata gat ggt gta acc cgg agt gac caa gga ttg Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu	290	295	971 300
tac acc tgt gca gca tcc agt ggg ctg atg acc aag aag aac agc aca Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr	305	310	1019 315
320			
ttt gtc agg gtc cat gaa aaa cct ttt gtt gct ttt gga agt ggc atg Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met	325	330	1067 335
gaa tct ctg gtg gaa gcc acg gtg ggg gag cgt gtc aga atc cct gcg Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala	340	345	1115 350
aag tac ctt ggt tac cca ccc cca gaa ata aaa tgg tat aaa aat gga Lys Tyr Leu Gly Tyr Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly	355	360	1163 365
ata ccc ctt gag tcc aat cac aca att aaa gcg ggg cat gta ctg acg Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr	370	375	1211 380
att atg gaa gtg agt gaa aga gac aca gga aat tac act gtc atc ctt Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu	385	390	1259 395
			400

acc aat ccc att tca aag gag aag cag agc cat gtg gtc tct ctg gtt	1307
Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val	
405 410 415	
gtg tat gtc cca ccc cag att ggt gag aaa tct cta atc tct cct gtg	1355
Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val	
420 425 430	
gat tcc tac cag tac ggc acc act caa acg ctg aca tgt acg gtc tat	1403
Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr	
435 440 445	
gcc att cct ccc ccg cat cac atc cac tgg tat tgg cag ttg gag gaa	1451
Ala Ile Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu	
450 455 460	
gag tgc gcc aac gag ccc agc cat gct gtc tca gtg aca aac cca tac	1499
Glu Cys Ala Asn Glu Pro Ser His Ala Val Ser Val Thr Asn Pro Tyr	
465 470 475 480	
cct tgt gaa gaa tgg aga agt gtg gag gac ttc cag gga gga aat aaa	1547
Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys	
485 490 495	
att gaa gtt aat aaa aat caa ttt gct cta att gaa gga aaa aac aaa	1595
Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys	
500 505 510	
act gta agt acc ctt gtt atc caa gcg gca aat gtg tca gct ttg tac	1643
Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr	
515 520 525	
aaa tgt gaa gcg gtc aac aaa gtc ggg aga gga gag agg gtg atc tcc	1691
Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser	
530 535 540	
ttc cac gtg acc agg ggt cct gaa att act ttg caa cct gac atg cag	1739
Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln	
545 550 555 560	
ccc act gag cag gag agc gtg tct ttg tgg tgc act gca gac aga tct	1787
Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser	
565 570 575	
acg ttt gag aac ctc aca tgg tac aag ctt ggc cca cag cct ctg cca	1835
Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro	
580 585 590	
atc cat gtg gga gag ttg ccc aca cct gtt tgc aag aac ttg gat act	1883
Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr	
595 600 605	
ctt tgg aaa ttg aat gcc acc atg ttc tct aat agc aca aat gac att	1931
Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile	
610 615 620	
ttg atc atg gag ctt aag aat gca tcc ttg cag gac caa gga gac tat	1979
Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr	
625 630 635 640	
gtc tgc ctt gct caa gac agg aag acc aag aaa aga cat tgc gtg gtc	2027
Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val	
645 650 655	
agg cag ctc aca gtc cta gag cgt gtg gca ccc acg atc aca gga aac	2075

Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn			
660	665	670	
ctg gaa aat cag acg aca agt att ggg gaa agc atc gaa gtc tca tgc		2123	
Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys			
675	680	685	
acg gca tct ggg aat ccc cct cca cag atc atg tgg tat aaa gat aat		2171	
Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn			
690	695	700	
gag acc ctt gta gaa gac tca ggc att gta ttg aag gat ggg aac cgg		2219	
Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg			
705	710	715	720
aac ctc act atc cgc aga gtg agg aag gag gac gaa ggc ctc tac acc		2267	
Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Ile Tyr Thr			
725	730	735	
tgc cag gca tgc agt gtt ctt ggc tgt gca aaa gtg gag gca ttt ttc		2315	
Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe			
740	745	750	
ata ata gaa ggt gcc cag gaa aag acg aac ttg gaa		2351	
Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu			
755	760		

<210> 85  
 <211> 764  
 <212> PRT  
 <213> Human

<400> 85

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu			
5	10	15	
Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro			
20	25	30	
Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr			
35	40	45	
Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro			
50	55	60	
Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser			
65	70	75	80
Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn			
85	90	95	
Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser			
100	105	110	
Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser			
115	120	125	
Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys			
130	135	140	
Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser			
145	150	155	160

Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg  
165 170 175

Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile  
180 185 190

Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser  
195 200 205

Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr  
210 215 220

Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu  
225 230 235 240

Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile  
245 250 255

Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu  
260 265 270

Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe  
275 280 285

Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu  
290 295 300

Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr  
305 310 315 320

Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met  
325 330 335

Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala  
340 345 350

Lys Tyr Leu Gly Tyr Pro Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly  
355 360 365

Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr  
370 375 380

Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu  
385 390 395 400

Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val  
405 410 415

Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val  
420 425 430

Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr  
435 440 445

Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu  
450 455 460

Glu Cys Ala Asn Glu Pro Ser His Ala Val Ser Val Thr Asn Pro Tyr  
465 470 475 480

Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys  
485 490 495

Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys  
500 505 510

Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr  
 515 520 525  
 Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser  
 530 535 540  
 Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln  
 545 550 555 560  
 Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser  
 565 570 575  
 Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro  
 580 585 590  
 Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr  
 595 600 605  
 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile  
 610 615 620  
 Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr  
 625 630 635 640  
 Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val  
 645 650 655  
 Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn  
 660 665 670  
 Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys  
 675 680 685  
 Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn  
 690 695 700  
 Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg  
 705 710 715 720  
 Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr  
 725 730 735  
 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe  
 740 745 750  
 Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu  
 755 760

<210> 86  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> amplification primer for VEGF

<400> 86

tcgggcctcc gaaaccatga

20

<210> 87  
 <211> 20  
 <212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for VEGF

<400> 87

cctggtgaga gatctggttc

20

<210> 88

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for Flt-1

<400> 88

tttgtgattt tggccttgc

19

<210> 89

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for Flt-1

<400> 89

caggctcatg aacttgaaag c

21

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for KDR

<400> 90

gtgaccaaca tggagtcgtg

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for KDR

<400> 91

ccagagattc catgccactt

20

<210> 92

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for KDR

<400> 92

tcatgttga gaccttcaa

19

<210> 93

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> amplification primer for KDR

<400> 93

gtctttgcgg atgtccacg

19

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
WO 2003/075840 A3

(51) International Patent Classification<sup>7</sup>: C07H 21/04,  
C07K 16/00, C12N 15/63, 15/85, 15/86

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/US2003/006459

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 4 March 2003 (04.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/361,783 4 March 2002 (04.03.2002) US

(71) Applicant (for all designated States except US): IM-  
CLONE SYSTEMS INCORPORATED [US/US]; 180  
Varick Street, New York, NY 10014 (US).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHU, Zhenping  
[US/US]; 9 Boulder Run, Oakland, NJ 07436 (US).

(74) Agents: SOMERVILLE, Deborah, A. et al.; Kenyon &  
Kenyon, One Broadway, New York, NY 10004 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(88) Date of publication of the international search report:  
29 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/075840 A3

(54) Title: HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF

(57) Abstract: The invention provides an antibodies that bind to *KDR* with an affinity comparable to or higher than human VEGF, and that neutralizes activation of *KDR*. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of *KDR*, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/06459

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C07K16/00; C12N 15/63, 15/85, 15/86  
 US CL : 435/320.1, 325; 530/388.15; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 530/388.15; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LU D, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer. January 2002, Vol. 97, pages 393-399; entire document.	1-3
X,E	US 2003/0108545 A1 (ROCKWELL et al.) 12 June 2003 (12.06.2003); entire document, particularly SEQ ID NOS: 24 and 26.	1-5, 8-10, and 14-1E7

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

10 December 2003 (10.12.2003)

Date of mailing of the international search report

10 MAR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Stephen L. Rawlings, Ph.D.

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/06459

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Please See Continuation Sheet

**Remark on Protest**  The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

PCT/US03/06459

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-17, drawn to an antibody.

Group II, claim(s) 18, 19, and 21, insofar as the claims are drawn to a method for inhibiting angiogenesis.

Group III, claim(s) 18 and 20-29, insofar as the claims are drawn to a method for reducing tumor growth.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

Claims 1 and 18-20 are generic to a plurality of species of invention wherein said antibody is selected from the group consisting of:

An antibody comprising a heavy chain domain and a light chain domain represented by SEQ ID NOs: 24 and 26, respectively;

An antibody comprising a heavy chain domain and a light chain domain represented by SEQ ID NOs: 24 and 53, respectively;

An antibody comprising a heavy chain domain represented by SEQ ID NO: 20;

An antibody comprising a heavy chain domain represented by SEQ ID NO: 31;

An antibody comprising a light chain domain represented by SEQ ID NO: 22;

An antibody comprising a light chain domain represented by SEQ ID NO: 29;

An antibody comprising a light chain domain represented by SEQ ID NO: 33;

An antibody comprising a light chain domain represented by SEQ ID NO: 35;

An antibody comprising a light chain domain represented by SEQ ID NO: 37;

An antibody comprising a light chain domain represented by SEQ ID NO: 39;

An antibody comprising a light chain domain represented by SEQ ID NO: 41;

An antibody comprising a light chain domain represented by SEQ ID NO: 43;

An antibody comprising a light chain domain represented by SEQ ID NO: 45;

An antibody comprising a light chain domain represented by SEQ ID NO: 47;

An antibody comprising a light chain domain represented by SEQ ID NO: 49; and

An antibody comprising a light chain domain represented by SEQ ID NO: 51.

Claim 20 is generic to a plurality of species of invention wherein said tumor is selected from the group consisting of:

(a) Tumor of the colon;

**INTERNATIONAL SEARCH REPORT**

PCT/US03/06459

- (b) Breast tumor; and
- (c) A non-solid tumor.

Claim 20 is further generic to a plurality of species of invention wherein said method further comprises administering an agent selected from the group consisting of:

- (1) An epidermal growth factor receptor antagonist;
- (2) *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1;
- (3) Chemotherapeutic agent; and
- (4) Radiation.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Lu et al. (*Int J Cancer*. 2002 Jan 20; 97 (3): 393-9) teach a human antibody that binds selectively to KDR.

The special technical feature of group I is an antibody.

The special technical feature of group II is inhibiting angiogenesis.

The special technical feature of group III is reducing tumor growth.

Groups I-III do not share the same or corresponding special technical feature so as to form a single general inventive concept under PCT Rules 13.1 and 13.2.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The special technical feature of species (a) of claim 1 is an antibody comprising SEQ ID NO: 26.

The special technical feature of species (b) of claim 1 is an antibody comprising SEQ ID NO: 53.

The special technical feature of species (c) of claim 1 is an antibody comprising SEQ ID NO: 20.

The special technical feature of species (d) of claim 1 is an antibody comprising SEQ ID NO: 31.

The special technical feature of species (e) of claim 1 is an antibody comprising SEQ ID NO: 22.

The special technical feature of species (f) of claim 1 is an antibody comprising SEQ ID NO: 29.

The special technical feature of species (g) of claim 1 is an antibody comprising SEQ ID NO: 33.

The special technical feature of species (h) of claim 1 is an antibody comprising SEQ ID NO: 35.

The special technical feature of species (i) of claim 1 is an antibody comprising SEQ ID NO: 37.

The special technical feature of species (j) of claim 1 is an antibody comprising SEQ ID NO: 39.

The special technical feature of species (k) of claim 1 is an antibody comprising SEQ ID NO: 41.

The special technical feature of species (l) of claim 1 is an antibody comprising SEQ ID NO: 43.

The special technical feature of species (m) of claim 1 is an antibody comprising SEQ ID NO: 45.

The special technical feature of species (n) of claim 1 is an antibody comprising SEQ ID NO: 47.

The special technical feature of species (o) of claim 1 is an antibody comprising SEQ ID NO: 49.

## INTERNATIONAL SEARCH REPORT

PCT/US03/06459

The special technical feature of species (p) of claim 1 is an antibody comprising SEQ ID NO: 51.

Accordingly, the species of invention encompassed by claims 1 and 18-20 do not have the same or corresponding special technical feature so as to form a single general inventive concept.

The special technical feature of species (a) of claim 20 is reducing the growth of a tumor of the colon.

The special technical feature of species (b) of claim 20 is reducing the growth of a breast tumor.

The special technical feature of species (c) of claim 20 is reducing the growth of a non-solid tumor.

Accordingly, the species of invention encompassed by claim 20 do not have the same or corresponding special technical feature so as to form a single general inventive concept.

The special technical feature of subspecies (1) of claim 20 is further administering an epidermal growth factor receptor antagonist.

The special technical feature of subspecies (2) of claim 20 is further administering *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

The special technical feature of subspecies (3) of claim 20 is further administering chemotherapeutic agent.

The special technical feature of subspecies (4) of claim 20 is further administering radiation.

Accordingly, the subspecies of invention encompassed by claim 20 do not have the same or corresponding special technical feature so as to form a single general inventive concept.

### Continuation of Box II Item 4:

Claims 1-5, 8-10, and 14-16, insofar as the claims are drawn to an antibody comprising SEQ ID NOs: 24 and 26.

### Continuation of B. FIELDS SEARCHED Item 3:

Databases GENESEQ, ISSUED PATENTS, PUBLISHED APPLICATIONS, PRI, SPTREMBL, SWISS PROTEIN: SEQ ID NOs: 24 and 26; WEST, MEDLINE: human anti-KDR antibody, D2C6.